Becton Dickinson (BDX)

Company ID: 114 | CIK: 0000010795
10-Q view:
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

No 10-Q data

Business Unit / Product Segments

No 10-Q data

Major Customers (% of Revenue)

No 10-Q data

Operational KPIs

Minimum purchase commitment revenue (backlog)

Product liability claims (claims_count)

Shareholders (customers)

No 10-Q data

People managers (headcount)

Inventory advanced to distributors (inventory_units)

No 10-K data

BGM product sales (other)

No 10-Q data

Brazil revenue share (other)

No 10-K data

COVID-19 revenue impact (other)

No 10-K data

COVID-19 testing revenue (other)

No 10-Q data

COVID-19 testing revenues (other)

No 10-Q data

Capital expenditures (other)

No 10-K data

CareFusion revenue contribution (other)

No 10-K data

Cash and short-term investments (other)

No 10-K data

Cash from operating activities (other)

No 10-K data

Cash held outside US (other)

No 10-K data

Claims settled (other)

No 10-K data

Class action lawsuits pending (other)

No 10-K data

Commercial Paper Outstanding (other)

No 10-K data

Commercial paper borrowings (other)

No 10-K data

Commercial paper borrowings outstanding (other)

No 10-K data

Commercial paper outstanding (other)

No 10-K data

Common Shares Outstanding (other)

No 10-Q data

Common Stock Outstanding (other)

No 10-Q data

Common shares outstanding (other)

Common shares repurchase authorization remaining (other)

No 10-K data

Common shares repurchased (other)

No 10-K data

Common stock outstanding (other)

No 10-Q data

Common stock repurchased (other)

No 10-K data

Common stock repurchases (other)

No 10-K data

Contract liabilities (other)

No 10-K data

Countries of operation (other)

No 10-Q data

Countries of operations (other)

No 10-Q data

Countries with associates (other)

No 10-Q data

Debt to capitalization (other)

No 10-K data

Debt to total capital (other)

No 10-K data

Debt-to-capitalization ratio (other)

No 10-K data

Discretionary pension contributions (other)

No 10-K data

Dividends paid (other)

No 10-K data

Effective income tax rate (other)

No 10-K data

Effective tax rate (other)

No 10-K data

Emerging market revenue (other)

No 10-Q data

Emerging market revenues (other)

No 10-Q data

Emerging markets revenue (other)

No 10-Q data

Employees remaining to sever (other)

No 10-K data

Employees severed (other)

No 10-K data

Ethylene oxide lawsuits (other)

Ethylene oxide litigation (other)

No 10-K data

Ethylene oxide plaintiffs (other)

No 10-K data

Expected litigation recoveries (other)

No 10-K data

FDA Warning Letter clearances (other)

No 10-K data

FDA Warning Letter liability (other)

No 10-K data

FDA clearances received (other)

No 10-K data

Female representation (other)

No 10-Q data

Filter product claims (other)

No 10-K data

Filter product liability claims (other)

No 10-K data

Foreign earnings repatriated (other)

No 10-K data

Full-year share repurchase plan (other)

No 10-K data

Gender representation (other)

No 10-Q data

Government receivables (other)

No 10-K data

Government receivables outstanding (other)

No 10-K data

Governmental receivables (other)

No 10-K data

Greek Government Receivables (other)

No 10-K data

Gross profit margin (other)

No 10-K data

Hernia product claims (other)

No 10-K data

Hernia product liability claims (other)

Implantable port product liability claims (other)

No 10-K data

Income tax rate (other)

No 10-K data

Interest coverage ratio (other)

No 10-K data

Interest expense coverage ratio (other)

No 10-K data

Latex claims received (other)

No 10-K data

Latex product liability lawsuits (other)

No 10-K data

Litigation accruals (other)

No 10-K data

Litigation reserves (other)

No 10-K data

Medical device excise tax (other)

No 10-K data

Medical safety device sales (other)

No 10-K data

Medical safety sales (other)

No 10-K data

Needle stick lawsuits (other)

No 10-K data

New product revenue share (other)

No 10-Q data

New products revenue share (other)

No 10-Q data

New share repurchase authorization (other)

No 10-K data

Number of Reportable Segments (other)

Number of Shareholders (other)

No 10-Q data

Operating cash flow (other)

No 10-K data

Operating margin (other)

No 10-K data

Pending product liability claims (other)

No 10-Q data

Positions eliminated (other)

No 10-K data

Preanalytical safety device sales (other)

No 10-K data

Preanalytical safety sales (other)

No 10-K data

Product liability accrual (other)

No 10-K data

Product liability accruals (other)

No 10-K data

Product liability claims (other)

Product liability reserves (other)

No 10-Q data

Product upgrades deployed (other)

No 10-K data

Qualified settlement funds (other)

No 10-K data

R&D Expense (other)

No 10-Q data

R&D expense ratio (other)

No 10-K data

Race representation (other)

No 10-Q data

Rebate liability (other)

No 10-K data

Receivables factored (other)

No 10-K data

Receivables factored outstanding (other)

No 10-K data

Remaining repurchase authorization (other)

No 10-K data

Remaining share repurchase authorization (other)

No 10-K data

Repurchase authorization remaining (other)

No 10-K data

Research and Development Spending (other)

No 10-Q data

Research and development expense (other)

Research and development expense ratio (other)

No 10-K data

Research and development spend (other)

No 10-Q data

Restructuring liability (other)

No 10-K data

Restructuring target positions (other)

No 10-K data

Revenue growth (other)

No 10-K data

Revolving credit facility (other)

No 10-K data

S&A expense ratio (other)

No 10-K data

Safety-engineered device sales (other)

Safety-engineered devices sales (other)

No 10-K data

Safety-engineered product sales (other)

Safety-engineered products sales (other)

No 10-K data

Safety-engineered sales (other)

Safety-engineered segment sales (other)

No 10-K data

Segment operating margin (other)

No 10-K data

Selling and administrative expense (other)

No 10-K data

Selling and administrative expense ratio (other)

No 10-K data

Settled product liability claims (other)

No 10-K data

Share repurchase authorization (other)

No 10-K data

Share repurchase authorization remaining (other)

No 10-K data

Share repurchase program capacity (other)

No 10-K data

Share repurchases (other)

No 10-K data

Share-based compensation expense (other)

No 10-K data

Shareholders (other)

No 10-Q data

Shareholders of Record (other)

No 10-Q data

Shareholders of record (other)

No 10-Q data

Shares Outstanding (other)

No 10-Q data

Shares authorized for repurchase (other)

No 10-K data

Shares available for repurchase (other)

No 10-K data

Shares available under repurchase program (other)

No 10-K data

Shares outstanding (other)

Shares remaining under repurchase authorization (other)

No 10-K data

Shares remaining under repurchase authorizations (other)

No 10-K data

Shares repurchased (other)

No 10-K data

Short-term debt (other)

No 10-K data

Short-term debt percentage (other)

No 10-K data

Short-term debt percentage of total debt (other)

No 10-K data

Short-term debt ratio (other)

No 10-K data

Short-term debt share of total debt (other)

No 10-K data

Short-term debt to total debt ratio (other)

No 10-K data

Spain government receivables (other)

No 10-K data

Supplier finance payables (other)

No 10-K data

Total Debt (other)

No 10-K data

Total debt (other)

No 10-K data

Total debt to total capital (other)

No 10-K data

Total debt to total capital ratio (other)

No 10-K data

Total investments (other)

No 10-K data

Underrepresented race representation (other)

No 10-Q data

Unrecognized share-based compensation (other)

No 10-K data

Unrecognized tax benefits (other)

No 10-K data

Weighted Average Cost of Debt (other)

No 10-K data

Weighted average cost of debt (other)

No 10-K data

Weighted average diluted shares (other)

No 10-K data

Weighted average shares (other)

No 10-K data

Women's Health claims settled (other)

No 10-K data

Women's Health product liability claims (other)

No 10-K data

Women's health claims settled (other)

No 10-K data

Women's health claims unfiled (other)

No 10-K data

Women's health product claims (other)

No 10-K data

Women's health product liability claims (other)

No 10-K data

Workforce diverse representation — gender (global) (other)

No 10-Q data

Workforce diverse representation — race (U.S. only) (other)

No 10-Q data

Workforce diversity (other)

No 10-Q data

Workforce diversity representation (other)

No 10-Q data

Workforce gender representation (other)

No 10-Q data

Workforce racial representation (other)

No 10-Q data

Worldwide revenue growth (reported) (other)

No 10-Q data

Y2000 plan cost incurred (other)

No 10-K data

Y2000 plan estimated total cost (other)

No 10-K data

Y2000 remediation completion (other)

No 10-K data

Y2000 testing completion (other)

No 10-K data

Y2K contingency planning completion (other)

No 10-K data

Y2K remediation completion (other)

No 10-K data

Y2K testing completion (other)

No 10-K data

Year 2000 Plan completion (other)

No 10-K data

Year 2000 program costs (other)

No 10-K data

Year 2000 remediation completion (other)

No 10-K data

Year 2000 testing completion (other)

No 10-K data

Facilities (properties)

No 10-Q data

Remaining performance obligations (rpo)

Shareholders of Record (shareholders)

No 10-Q data

Common stock outstanding (shares)

No 10-Q data

Common stock shares outstanding (shares_outstanding)

No 10-Q data

Square Footage (square_footage)

No 10-Q data

Safety-engineered device sales (units_shipped)

No 10-K data
Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

No 10-Q data

Demographics

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Workforce Breakdowns

No 10-Q data
No 10-Q data

HCM Metrics — Point-in-Time

No 10-Q data

HCM Metrics — Flow (Annual / YTD)

No flow HCM metrics found.

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-06-30restructuringin_progressCompany-wide (all four reportable segments)USD 605 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Nine-month charge to expense; includes $64M employee-termination accrual and $541M other costs, of which $450M is non-cash asset impairment recorded in Q2 FY2026 upon commitment to exit activities under the Excellence Unleashed strategy. No employee count, announcement date, or completion date disclosed.
2026-06-30divestiture_reductioncompleted2026-02-09Life Sciences segment (Biosciences and Diagnostic Solutions business)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off and combination with Waters Corporation completed 2026-02-09; former segment eliminated from reporting structure. Employees transferring to the spin-off entity are referenced only via share-based award conversions — no headcount disclosed.
2026-06-30restructuringin_progress2026-03-31GlobalAll segmentsUSD 450 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Non-cash asset impairment charges recorded in Q2 2026 upon commitment to exit certain operational activities and projects under 'Excellence Unleashed' strategy. Employee count not disclosed.
2026-06-30restructuringin_progress2026-03-31GlobalAll segmentsUSD 64 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs charged to expense in the nine months ended June 30, 2026. Specific headcount affected not disclosed.
2026-06-30divestiture_reductioncompleted2026-02-092026-02-09GlobalLife Sciences (Discontinued Operations)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Spin-off of Biosciences and Diagnostic Solutions business to Waters Corporation. Headcount transferred not explicitly quantified in this filing.
2026-06-30restructuringin_progressEmployee Severance [Member]USD 64,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-30restructuringin_progressOther Restructuring [Member]USD 541,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-06-30restructuringin_progressUSD 605,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressGlobalAll segmentsUSD 557 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cost-saving and simplification program under 'Excellence Unleashed' strategy; includes $450M non-cash asset impairment. Employee headcount impact not disclosed.
2026-03-31divestiture_reductioncompleted2026-02-092026-02-09GlobalLife Sciences (Biosciences and Diagnostic Solutions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off of Biosciences and Diagnostic Solutions business combined with Waters Corporation via Reverse Morris Trust. Headcount transferred not disclosed.
2026-03-31restructuringin_progressGlobalAll segmentsUSD 450 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Non-cash asset impairment charges of $450 million recorded in Q2 FY2026 upon commitment to exit certain operational activities and projects under 'Excellence Unleashed' strategy. Employee termination charges of $62 million also recorded in the period. Specific headcount affected by these actions is not disclosed.
2026-03-31divestiture_reductioncompleted2026-02-092026-02-09GlobalLife Sciences (Discontinued Operations)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Spin-off of former Biosciences and Diagnostic Solutions business completed on Feb 9, 2026. All outstanding BD share-based awards for former business employees transferred to Waters. Specific headcount transferred is not disclosed.
2026-03-31restructuringin_progressEmployee Severance [Member]USD 62,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressOther Restructuring [Member]USD 495,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressUSD 557,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-12-31restructuringin_progressGlobalAll segmentsUSD 75 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employee termination component charged $41M during the quarter; liability balance $47M at quarter-end. No employee headcount disclosed. Program covers simplification, cost-saving, supply chain, and manufacturing footprint initiatives.
2025-12-31divestiture_reductioncompleted2026-02-09GlobalLife Sciences (Biosciences and Diagnostic Solutions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off of Biosciences and Diagnostic Solutions business combined with Waters Corporation via Reverse Morris Trust; completed 2026-02-09. No employee headcount associated with the divestiture disclosed. Life Sciences segment will be eliminated from segment reporting going forward.
2025-12-31restructuringin_progressGlobalAll segmentsUSD 75 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to simplification and cost-saving initiatives including organizational realignment for Biosciences/Diagnostic Solutions separation, supply chain optimization, and manufacturing footprint streamlining. Employee count not disclosed.
2025-12-31divestiture_reductioncompleted2026-02-092026-02-09GlobalLife Sciencessubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Spin-off of Biosciences and Diagnostic Solutions business and combination with Waters Corporation. Headcount removed not explicitly quantified in this filing.
2025-12-31restructuringin_progressEmployee Severance [Member]USD 41,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-12-31restructuringin_progressOther Restructuring [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-12-31restructuringin_progressUSD 75,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressAll segments — company-wide simplification and cost-saving initiativesUSD 45 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2025 restructuring expense of $275M comprised $45M employee termination costs and $230M other costs (project management, facility exits, inventory write-offs, asset impairments). No affected headcount disclosed. Restructuring liability of $63M remained at September 30, 2025. Charge reflects current-fiscal-year activity only.
2025-09-30divestiture_reductionannounced2025-07-132026-03Life Sciences — Biosciences and Diagnostic Solutions organizational unitsUSD 97 (millions)Item_1_Business
f5-10k / GLM-5.3-flash-HTML		Reverse Morris Trust transaction: Biosciences and Diagnostic Solutions business to be spun off to BD shareholders and merged with Waters; BD shareholders expected to hold ~39.2% of combined company and BD to receive ~$4B cash distribution. FY2025 separation-related costs of $97M recorded in Other operating expense. No headcount disclosed; closing expected around end of calendar Q1 2026 subject to regulatory, shareholder and IRS approvals.
2025-09-30restructuringin_progressGlobalAll segments — simplification and cost-saving initiativesUSD 45 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2025 employee-termination component of restructuring expense; total FY2025 restructuring charge was $275M, including $230M of non-employee costs (project management, facility exits, asset impairments). No employees-affected count disclosed; $63M restructuring liability remained at 2025-09-30.
2025-09-30divestiture_reductionannounced2025-07-132026-03-31GlobalLife Sciences — Biosciences and Diagnostic Solutionsother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Reverse Morris Trust announced 2025-07-13; expected to close around end of Q1 calendar 2026, subject to regulatory and other conditions. No headcount associated with the transaction disclosed; $97M of separation-related costs recorded in FY2025.
2025-09-30restructuringcompleted2025-10-01GlobalEnterprise — reorganization into five reportable segmentsother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Organizational units reorganized into five separately-managed segments effective 2025-10-01 (after fiscal year end); no headcount impact or associated charge disclosed.
2025-09-30restructuringin_progressGlobalAll segmentsUSD 275 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Costs primarily associated with simplification and other cost-saving initiatives including supply chain optimization, manufacturing footprint streamlining, and quality improvements. Employee count not explicitly disclosed in footnote.
2025-09-30acquisition_additioncompleted2024-09-03GlobalMedical Segment (Advanced Patient Monitoring)business_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Edwards Lifesciences’ Critical Care product group completed September 3, 2024. Headcount added not explicitly quantified.
2025-09-30restructuringin_progressGlobalAll segmentsUSD 275 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges related to simplification and cost-saving initiatives including employee terminations and other costs.
2025-09-30acquisition_additioncompleted2024-09-03GlobalMedicalbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Edwards Lifesciences' Critical Care product group (Advanced Patient Monitoring). Headcount not explicitly disclosed.
2025-09-30restructuringin_progressEmployee Severance [Member]USD 45,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-30restructuringin_progressOther Restructuring [Member]USD 230,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-30restructuringin_progressUSD 275,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-06-30restructuringin_progressGlobalAll segmentsUSD 187 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing simplification and cost-saving program; $187M charged to expense in the nine months ended June 30, 2025 (employee termination $62M, other $125M); restructuring liability of $76M at quarter-end. No employee counts or completion date disclosed.
2025-06-30divestiture_reductionannounced2025-07-132026-03-31GlobalLife Sciences — Biosciences and Diagnostic Solutionssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Post-quarter agreement to combine the Biosciences and Diagnostic Solutions business with Waters via a Reverse Morris Trust; expected to close around the end of calendar Q1 2026. No headcount impact disclosed.
2025-06-30restructuringin_progressGlobalAll segmentsUSD 58 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs charged to expense for the three months ended June 30, 2025. Part of simplification and cost-saving initiatives.
2025-06-30restructuringin_progressGlobalAll segmentsUSD 187 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs charged to expense for the nine months ended June 30, 2025. Part of simplification and cost-saving initiatives.
2025-06-30restructuringin_progressEmployee Severance [Member]USD 62,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressOther Restructuring [Member]USD 125,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressUSD 187,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressGlobalAll segmentsUSD 63 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Restructuring costs related to simplification and other cost-saving initiatives for the three months ended March 31, 2025. Employee count not disclosed.
2025-03-31restructuringin_progressGlobalAll segmentsUSD 129 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Restructuring costs related to simplification and other cost-saving initiatives for the six months ended March 31, 2025. Employee count not disclosed.
2025-03-31restructuringin_progressGlobalAll segmentsUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs charged to expense for the six months ended March 31, 2025.
2025-03-31restructuringin_progressGlobalAll segmentsUSD 94 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Other restructuring costs (non-employee-related, e.g., facility exit, project management) charged to expense for the six months ended March 31, 2025.
2025-03-31restructuringin_progressEmployee Severance [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressOther Restructuring [Member]USD 94,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressUSD 129,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-12-31restructuringin_progressGlobalAll segmentsUSD 66 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employee termination component of $20M charged in Q1 FY2025; balance of $47M at quarter-end. No employee count disclosed.
2024-12-31divestiture_reductionannounced2025-02-052026-09-30GlobalBiosciences and Diagnostic Solutions (Life Sciences segment)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced intention to separate; specifics expected by end of FY2025, targeting completion in FY2026. No headcount impact disclosed.
2024-12-31restructuringin_progressGlobalAll segmentsUSD 66 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to simplification and cost-saving initiatives including supply chain optimization and manufacturing footprint streamlining. Employee termination costs were $20 million; other costs were $46 million. No specific headcount reduction disclosed.
2024-12-31acquisition_additioncompleted2024-09-03GlobalMedicalbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Edwards Lifesciences' Critical Care product group (renamed Advanced Patient Monitoring). Headcount added not explicitly disclosed.
2024-12-31restructuringin_progressEmployee Severance [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-12-31restructuringin_progressOther Restructuring [Member]USD 46,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-12-31restructuringin_progressUSD 66,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressAll segmentsUSD 387 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Fiscal 2024 charges for simplification and cost-saving initiatives across all segments; comprises $80 million employee termination costs and $307 million other costs (facility exits, inventory write-offs, long-lived asset impairments). Restructuring liability of $60 million remained at September 30, 2024. Affected employee headcount not disclosed.
2024-09-30acquisition_additioncompleted2024-09-03Medical segment — Advanced Patient Monitoring unitbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Edwards Lifesciences' Critical Care product group completed September 3, 2024 for $3.911 billion; renamed BD Advanced Patient Monitoring within the Medical segment. Employee headcount added via the acquisition was not disclosed; announcement_date reflects the completion date.
2024-09-30restructuringin_progressGlobalAll segmentsUSD 387 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2024 restructuring costs related to simplification and cost-saving initiatives; employee termination component of $80M charged in FY2024; no employee count disclosed
2024-09-30acquisition_additioncompleted2024-09-032024-09-03GlobalMedical segment — Advanced Patient MonitoringUSD 3,911 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Edwards Lifesciences' Critical Care product group renamed BD Advanced Patient Monitoring; headcount added not disclosed; acquired business represents ~2% of consolidated total assets
2024-09-30restructuringcompletedGlobalAll SegmentsUSD 387 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Fiscal year 2024 restructuring expense of $387 million related to simplification and cost-saving initiatives. Employee termination costs were $80 million; other non-employee costs were $307 million.
2024-09-30acquisition_additioncompleted2024-09-03GlobalMedicalbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Edwards Lifesciences’ Critical Care product group (renamed BD Advanced Patient Monitoring) completed on September 3, 2024. Headcount not explicitly disclosed.
2024-09-30restructuringin_progressUSD 387 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges related to simplification and other cost-saving initiatives. Employee termination charges were $80 million; other restructuring costs were $307 million. Specific headcount affected not disclosed.
2024-09-30acquisition_additioncompleted2024-09-03Medicalbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Edwards Lifesciences' Critical Care product group (renamed BD Advanced Patient Monitoring). Headcount added not explicitly disclosed.
2024-09-30restructuringin_progressEmployee Severance [Member]USD 80,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-30restructuringin_progressOther Restructuring [Member]USD 307,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-30restructuringin_progressUSD 387,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-06-30restructuringin_progressGlobalAll segmentsUSD 262 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring costs charged to expense in nine months ended June 30, 2024, related to simplification and cost-saving initiatives; employee termination portion was $45M. No employee count disclosed.
2024-06-30acquisition_additionannounced2024-06-032024-12-31GlobalBD Medical / Critical Care product groupUSD 4,200 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2B cash; expected close by end of calendar 2024. No headcount associated with the transaction disclosed.
2024-06-30restructuringin_progressGlobalAll segmentsUSD 262 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to simplification and cost-saving initiatives including supply chain optimization and manufacturing footprint streamlining. Employee termination charges were $45 million; other restructuring costs were $217 million. Specific headcount affected not disclosed.
2024-06-30restructuringin_progressEmployee Severance [Member]USD 45,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressOther Restructuring [Member]USD 217,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressUSD 262,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressGlobalAll segmentsUSD 167 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six-month charge for simplification and cost-saving initiatives; includes $60M employee termination and $107M other costs. No employee count disclosed.
2024-03-31restructuringin_progressUSD 101 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Incurred restructuring costs primarily in connection with simplification and other cost-saving initiatives. Employee termination charges were $60 million; other costs were $107 million. No specific employee count disclosed.
2024-03-31restructuringin_progressEmployee Severance [Member]USD 60,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressOther Restructuring [Member]USD 107,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressUSD 167,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-12-31restructuringin_progressGlobalAll segmentsUSD 69 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Simplification and cost-saving initiatives; $69M charged to expense in the quarter (employee termination $35M, other $34M). Restructuring liability was $81M at 2023-12-31. Number of employees affected and completion date not disclosed.
2023-12-31restructuringin_progressUSD 75 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Incurred costs primarily in connection with simplification and other cost-saving initiatives. Employee termination charges were $35 million; other costs (project management, asset write-offs) were $34 million. No specific employee headcount affected was disclosed.
2023-12-31restructuringin_progressEmployee Severance [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-12-31restructuringin_progressOther Restructuring [Member]USD 34,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-12-31restructuringin_progressUSD 69,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-09-30restructuringin_progressAll segments — simplification and cost-saving initiativesUSD 239 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Fiscal 2023 charges of $239 million (of which $117 million employee termination costs) for simplification and other cost-saving initiatives; $80 million restructuring liability (mostly employee termination) remained at September 30, 2023. Affected-employee headcount not disclosed.
2023-09-30divestiture_reductioncompleted2023-062023-08BD Interventional — Surgical Instrumentation platformother
f5-10k / GLM-5.3-flash-HTML		Sale completed August 2023 pursuant to a definitive agreement signed June 2023; pre-tax gain of approximately $268 million and net proceeds of $540 million. Headcount transferred with the business was not disclosed; historical results not classified as discontinued operations.
2023-09-30restructuringin_progressGlobalAll segmentsUSD 239 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2023 restructuring charges tied to simplification and cost-saving initiatives; employee count not disclosed; restructuring liability balance at FY2023 year-end was $80 million
2023-09-30divestiture_reductioncompleted2023-06-302023-08-31GlobalInterventional — Surgical Instrumentation platformdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale completed August 2023 under agreement signed June 2023; pre-tax gain of approximately $268 million recognized; associated headcount not disclosed; results not classified as discontinued operations
2023-09-30restructuringcompletedGlobalMultipleUSD 239 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges primarily related to simplification and cost saving initiatives. Employee termination costs were $117 million; other costs were $122 million.
2023-09-30acquisition_additioncompleted2022-07-18GlobalMedical - Medication Management SolutionsItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Parata Systems completed July 18, 2022. Financial results reported within Medical segment.
2023-09-30divestiture_reductioncompleted2023-06-012023-08-31GlobalInterventional - Surgical InstrumentationItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Sale of Interventional segment’s Surgical Instrumentation platform completed in August 2023.
2023-09-30divestiture_reductioncompleted2022-04-012022-04-01GlobalMedical - Diabetes CareItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Spin-off of Diabetes Care business (Embecta Corp.) completed April 1, 2022. Reflected as discontinued operations.
2023-09-30restructuringcompletedGlobalAll segmentsUSD 239 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges primarily related to simplification and cost saving initiatives. Employee termination liability balance increased from $24M to $79M during the year.
2023-09-30acquisition_additioncompleted2022-07-18GlobalMedical - Medication Management SolutionsItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Parata Systems completed July 18, 2022. Headcount not explicitly disclosed.
2023-09-30divestiture_reductioncompleted2023-06-012023-08-01GlobalInterventional - Surgical InstrumentationItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Sale of Surgical Instrumentation platform completed August 2023. Headcount not explicitly disclosed.
2023-09-30divestiture_reductioncompleted2022-03-222022-04-01GlobalMedical - Diabetes CareItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Spin-off of Embecta Corp. (Diabetes Care business) completed April 1, 2022. Headcount not explicitly disclosed.
2023-09-30restructuringin_progressEmployee Severance [Member]USD 117,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-09-30restructuringin_progressOther Restructuring [Member]USD 122,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-09-30restructuringin_progressUSD 239,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-06-30restructuringin_progressAll segmentsUSD 120 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Simplification and cost-saving program; $120M charged to expense in nine months ended 2023-06-30 ($46M employee termination, $74M other); severance liability balance $45M at quarter-end. No employee counts or completion dates disclosed.
2023-06-30divestiture_reductionannounced2023-06-302023-08-31Interventional — Surgical Instrumentation platformother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Surgical Instrumentation platform signed June 2023, completed August 2023; gross proceeds ~$540M. No headcount impact disclosed.
2023-06-30restructuringin_progressUSD 46 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs charged to expense for the nine months ended June 30, 2023. No employee count disclosed.
2023-06-30restructuringin_progressUSD 74 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Other restructuring costs (project management, asset write-offs) charged to expense for the nine months ended June 30, 2023.
2023-06-30restructuringin_progressEmployee Severance [Member]USD 46,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressOther Restructuring [Member]USD 74,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-06-30restructuringin_progressUSD 120,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressGlobalAll segmentsUSD 59 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring costs charged to expense during six months ended March 31, 2023, primarily for simplification and cost-saving initiatives across all segments. Employee headcount impact not disclosed. Restructuring liability balance was $23M at March 31, 2023.
2023-03-31restructuringin_progressUSD 106 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Company incurred restructuring costs primarily in connection with simplification and other cost saving initiatives. Employee termination charges were $10 million and other restructuring costs were $49 million for the six months ended March 31, 2023. No specific employee headcount affected was disclosed.
2023-03-31restructuringin_progressEmployee Severance [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressOther Restructuring [Member]USD 49,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-03-31restructuringin_progressUSD 59,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-12-31restructuringin_progressUSD 26 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to simplification and cost saving initiatives. Employee termination charges were $4 million; other restructuring charges were $22 million. No employee count disclosed.
2022-12-31restructuringin_progressEmployee Severance [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-12-31restructuringin_progressOther Restructuring [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-12-31restructuringin_progressUSD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-09-30divestiture_reductioncompleted2022-04-012022-04-01Medical segment — Diabetes Care businessUSD 30 (millions)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		BD completed the separation and distribution of Embecta Corp., formerly the Diabetes Care business (previously a unit of the Medical segment), on April 1, 2022; date shown is the completion date per the filing. Employees transferred to Embecta are not quantified in the filing. BD incurred $30 million of fiscal 2022 separation costs, recorded within Income from Discontinued Operations, Net of Tax.
2022-09-30restructuringin_progressAll segments — simplification and other cost-saving initiativesUSD 123 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Fiscal 2022 portion of an ongoing multi-year program tied to simplification and other cost-saving initiatives. Charges of $123 million comprised $21 million of employee termination costs and $103 million of other costs (including $19 million of non-cash asset impairments); components may not sum due to rounding. Employees affected are not disclosed; the restructuring liability stood at $35 million ($24 million employee termination) at September 30, 2022.
2022-09-30acquisition_additioncompleted2022-07-182022-07-18Medical segment — Medication Management Solutions unitUSD 1,548 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Completed acquisition of Parata Systems, a pharmacy automation provider, on July 18, 2022 (date shown is the completion date). Total cash consideration was $1.548 billion; headcount added was not disclosed. Parata's results are reported within the Medication Management Solutions unit since the acquisition date.
2022-09-30acquisition_additioncompletedbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Various other strategic acquisitions completed during fiscal 2022 that were not material individually or in the aggregate, including MedKeeper, Scanwell Health, Tissuemed and Venclose; individual consideration and headcount were not disclosed.
2022-09-30divestiture_reductioncompleted2022-04-012022-04-01GlobalMedical segment — Diabetes Care business (spun off as Embecta Corp.)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Employees transferred to Embecta; no headcount disclosed. $30M of spin-off execution costs recorded within discontinued operations in FY2022
2022-09-30acquisition_additioncompleted2022-07-182022-07-18United StatesMedical segment — Medication Management Solutions (Parata Systems pharmacy automation)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Total cash consideration $1.548 billion; acquired headcount not disclosed. Other FY2022 acquisitions (MedKeeper, Scanwell Health, Tissuemed, Venclose) were not material individually or in the aggregate
2022-09-30restructuringin_progressGlobalAll segments — simplification and other cost saving initiatives, plus system integration costsUSD 123 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2022 restructuring expense of $123M ($21M employee termination, $103M other); includes $19M non-cash asset impairment charges. Employees affected not disclosed; restructuring liability balance $35M at 2022-09-30
2022-09-30restructuringcompletedGlobalAll segmentsUSD 123 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Charges incurred in connection with simplification and other cost saving initiatives. Employee count not disclosed.
2022-09-30acquisition_additioncompleted2022-07-18GlobalMedicalbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Parata Systems for $1.548 billion. Headcount added not explicitly disclosed.
2022-09-30restructuringcompletedGlobalVariousUSD 123 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges related to simplification and other cost saving initiatives. Employee termination liability balance decreased from $14M to $24M; other restructuring liability decreased from $5M to $11M. Specific headcount affected not disclosed.
2022-09-30divestiture_reductioncompleted2022-04-012022-04-01GlobalDiabetes Carediscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Spin-off of Diabetes Care business into Embecta Corp. on April 1, 2022. Headcount transferred not explicitly quantified in the filing.
2022-09-30restructuringin_progressEmployee Severance [Member]USD 21,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-09-30restructuringin_progressOther Restructuring [Member]USD 103,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-09-30restructuringin_progressUSD 123,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2022-06-30restructuringin_progressUSD 72 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred during the nine months ended June 30, 2022, primarily in connection with simplification and other cost saving initiatives. Employee termination charges were $7 million; other restructuring charges were $65 million. No specific employee headcount affected was disclosed.
2022-06-30divestiture_reductioncompleted2022-04-01Diabetes Carebusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Spin-off of Diabetes Care business as Embecta Corp. on April 1, 2022. All outstanding BD share-based awards granted to Embecta employees were converted into Embecta awards. Specific headcount transferred was not disclosed.
2022-06-30restructuringin_progressEmployee Severance [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressOther Restructuring [Member]USD 65,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-06-30restructuringin_progressUSD 72,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressAll segmentsUSD 34 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Simplification and cost-saving initiatives; $34M charged to expense in six months ended 2022-03-31, of which $4M related to employee termination. No employee count disclosed.
2022-03-31divestiture_reductioncompleted2022-04-01GlobalDiabetes Care (Medical segment)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off of Diabetes Care business as Embecta Corp. completed 2022-04-01; historical results to be reclassified as discontinued operations. No headcount associated with the spin-off disclosed.
2022-03-31restructuringin_progressUSD 4 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs charged to expense for the six months ended March 31, 2022. No employee count disclosed.
2022-03-31divestiture_reductioncompleted2022-04-012022-04-01Diabetes Caresubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Spin-off of Diabetes Care business as Embecta Corp. completed on April 1, 2022. BD retains no ownership interest. Employee count transferred not disclosed.
2022-03-31restructuringin_progressEmployee Severance [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressOther Restructuring [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2022-03-31restructuringin_progressUSD 34,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-12-31divestiture_reductionannounced2021-05-062022-04-01GlobalDiabetes Care (Medical segment)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Spin-off of Diabetes Care as Embecta Corp.; board approved 2022-02-01 with distribution date 2022-04-01. No employee count disclosed.
2021-12-31restructuringin_progressGlobalAll segmentsUSD 17 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Simplification and cost-saving initiatives; $17M charged to expense in Q1 FY2022. No employee headcount affected disclosed.
2021-12-31acquisition_additioncompletedGlobalLife Sciences; InterventionalUSD 415 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisitions of Scanwell Health, Tissuemed, and Venclose during Q1 FY2022; $415M cash paid. No headcount added disclosed.
2021-12-31restructuringin_progressUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred primarily in connection with simplification and other cost saving initiatives focused on reducing complexity and improving cost efficiency.
2021-12-31restructuringin_progressEmployee Severance [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-12-31restructuringin_progressOther Restructuring [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-12-31restructuringin_progressUSD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-09-30divestiture_reductionannounced2021-05-06Diabetes Care (BD Medical segment)USD 35 (millions)MD&A
f5-10k / GLM-5.3-flash-HTML		Announced intention to spin off Diabetes Care as a separate public company in a tax-free transaction, expected to complete in the first half of calendar 2022, subject to board approval and Form 10 effectiveness. Fiscal 2021 charge represents consulting, legal, tax and advisory separation costs, not severance. Headcount impact of the spin-off not disclosed.
2021-09-30restructuringin_progressUSD 3 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year restructuring program stemming from the 2018 Bard acquisition. Fiscal 2021 charges: $1M employee termination (severance) plus $2M other. Employee termination liability of $10M remained at September 30, 2021. Number of employees affected not disclosed.
2021-09-30restructuringin_progressAll segments (simplification and other cost saving initiatives)USD 47 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Simplification and other cost saving initiatives aimed at reducing complexity and improving cost efficiency across all segments. Fiscal 2021 charges: $13M employee termination (severance) plus $34M other. Employee termination liability of $4M at September 30, 2021. Number of employees affected not disclosed. Combined fiscal 2021 restructuring charges for both components totaled $50M.
2021-09-30restructuringin_progressGlobalAll segmentsUSD 50 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2021 expense for simplification and cost saving initiatives ($47M) plus Bard-related charges ($3M); no employee counts or completion dates disclosed
2021-09-30acquisition_additioncompletedUnited StatesInterventionalMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Tepha, Inc. acquired in Q4 FY2021; headcount added not disclosed
2021-09-30divestiture_reductionannounced2021-05-062022-06-30GlobalMedical — Diabetes CareMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Planned tax-free spin-off as separate public company, expected first half of calendar 2022; $35M of separation advisory costs recorded in FY2021; headcount affected not disclosed
2021-09-30restructuringcompletedGlobalAll SegmentsUSD 185 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Total restructuring costs of $185 million recorded in 2021, including $135 million integration costs and $50 million restructuring costs related to simplification and cost saving initiatives. Employee headcount affected not explicitly disclosed.
2021-09-30restructuringcompletedGlobalAll segmentsUSD 50 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Restructuring costs related to simplification and cost saving initiatives. Employee count not disclosed.
2021-09-30restructuringcompletedGlobalAll segmentsUSD 135 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Integration costs related to Bard acquisition and other initiatives. Employee count not disclosed.
2021-09-30restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-09-30restructuringin_progressEmployee Severance [Member] / Other Initiatives [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-09-30restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-09-30restructuringin_progressOther Restructuring [Member] / Other Initiatives [Member]USD 34,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-09-30restructuringin_progressCR Bard Inc [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-09-30restructuringin_progressOther Initiatives [Member]USD 47,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2021-06-30restructuringin_progressAll segmentsUSD 33 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Simplification and cost-saving initiatives; $33M charged to expense for the nine months ended 2021-06-30, of which $12M relates to employee termination (Bard $1M, other initiatives $11M). No employee counts, announcement date, or completion date disclosed.
2021-06-30restructuringin_progressUSD 31 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to simplification and cost saving initiatives for the nine months ended June 30, 2021. Employee count not disclosed.
2021-06-30restructuringin_progressUSD 11 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to Bard acquisition integration for the nine months ended June 30, 2021. Employee count not disclosed.
2021-06-30restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressEmployee Severance [Member] / Other Initiatives [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressOther Restructuring [Member] / Other Initiatives [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressCR Bard Inc [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-06-30restructuringin_progressOther Initiatives [Member]USD 31,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred during the six months ended March 31, 2021, primarily in connection with simplification and other cost saving initiatives. Employee termination charges were $9 million and other restructuring charges were $26 million.
2021-03-31restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressEmployee Severance [Member] / Other Initiatives [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressOther Restructuring [Member] / Other Initiatives [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressCR Bard Inc [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2021-03-31restructuringin_progressOther Initiatives [Member]USD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-12-31restructuringin_progressUSD 17 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 FY2021 charges of $17M ($1M Bard-related, $16M other simplification/cost-saving initiatives) recorded within Acquisitions and other restructurings; employee-termination liability balance of $26M at 2020-12-31 ($13M Bard, $13M other). No employee counts, announcement date, or completion date disclosed.
2020-12-31restructuringin_progressUSD 16 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred primarily in connection with simplification and other cost saving initiatives. Employee termination charges were $6 million; other restructuring charges were $10 million. No specific headcount affected was disclosed.
2020-12-31restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 0 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-12-31restructuringin_progressEmployee Severance [Member] / Other Initiatives [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-12-31restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-12-31restructuringin_progressOther Restructuring [Member] / Other Initiatives [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-12-31restructuringin_progressCR Bard Inc [Member]USD 1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-12-31restructuringin_progressOther Initiatives [Member]USD 16,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-09-30restructuringin_progressCompany-wide (legacy Bard integration)USD 49 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Fiscal 2020 activity only of multi-year program begun with the December 2017 Bard acquisition. Includes $7 million of employee termination charges; the remaining $42 million largely represents non-cash conversion of pre-acquisition Bard equity awards rather than severance. Restructuring liability of $16 million remained at fiscal year-end. No affected headcount disclosed.
2020-09-30restructuringin_progressCompany-wide simplification and cost-saving initiativesUSD 46 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Fiscal 2020 charges comprise $13 million of employee termination costs and $33 million of other restructuring costs under initiatives implemented in fiscal 2020. Restructuring liability of $20 million remained at fiscal year-end. No affected headcount disclosed.
2020-09-30acquisition_additioncompletedMD&A
f5-10k / GLM-5.3-flash-HTML		Straub Medical AG acquired in the third quarter of fiscal 2020. Fiscal 2020 acquisition cash outflows of $164 million (net of cash acquired) primarily reflected this transaction; headcount added was not disclosed.
2020-09-30othercompletedManufacturingMD&A
f5-10k / GLM-5.3-flash-HTML		Temporary work reductions for certain manufacturing teams enacted as COVID-19 cost containment; no headcount or dates disclosed. Related measures included temporary executive pay reductions and suspension of defined contribution plan matching effective May 1, 2020, reinstated in October 2020.
2020-09-30restructuringin_progressGlobalCompany-wideUSD 95 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2020 restructuring costs related to simplification and other cost saving initiatives; employee affected count not disclosed
2020-09-30restructuringin_progressGlobalCompany-wideUSD 214 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2020 integration costs largely from C.R. Bard acquisition; employee affected count not disclosed
2020-09-30acquisition_additioncompletedGlobalInterventional / Medicalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Straub Medical AG completed in Q3 FY2020; headcount added not disclosed
2020-09-30divestiture_reductioncompletedGlobalLife Sciencesother
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Prior-year divestitures (2018) referenced for context; no FY2020 divestiture headcount disclosed
2020-09-30restructuringcompletedGlobalGlobalUSD 95 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Fiscal year 2020 restructuring costs primarily related to simplification and other cost saving initiatives. Employee count not disclosed.
2020-09-30acquisition_additioncompletedGlobalGlobalbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of Straub Medical AG completed in Q3 2020. Employee count not disclosed.
2020-09-30restructuringcompletedGlobalVariousUSD 95 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Includes costs related to simplification and other cost saving initiatives implemented in fiscal 2020, as well as integration costs from prior acquisitions.
2020-09-30restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-09-30restructuringin_progressEmployee Severance [Member] / Other Initiatives [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-09-30restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 42,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-09-30restructuringin_progressOther Restructuring [Member] / Other Initiatives [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-09-30restructuringin_progressCR Bard Inc [Member]USD 49,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-09-30restructuringin_progressOther Initiatives [Member]USD 46,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2020-06-30restructuringin_progressUSD 74 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred in connection with the acquisition of Bard and portfolio rationalization initiatives. Employee count not disclosed.
2020-06-30restructuringin_progressUSD 235 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD charges incurred in connection with the acquisition of Bard and portfolio rationalization initiatives. Employee count not disclosed.
2020-06-30restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressEmployee Severance [Member] / Other Initiatives [Member]USD -1,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressOther Restructuring [Member] / Other Initiatives [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressCR Bard Inc [Member]USD 40,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-06-30restructuringin_progressOther Initiatives [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressUSD 41 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing restructuring tied to the C.R. Bard acquisition and portfolio rationalization; six-month employee termination charges of $29M (Bard) and $(2)M (other initiatives), plus other charges of $23M and $14M. No employee counts disclosed.
2020-03-31layoffin_progressUnited StatesManufacturingMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		COVID-19 cost containment measures included temporary work reductions for certain manufacturing teams, along with travel restrictions, temporary executive pay reductions, and suspended matching contributions. No headcount or charge quantified.
2020-03-31restructuringin_progressUSD 161 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred in connection with the acquisition of Bard and portfolio rationalization initiatives. Employee termination liability balance decreased from $53M to $22M; other restructuring liability decreased from $4M to $12M.
2020-03-31otherin_progressGlobalMD&A
f5-10q / Qwen3.6-27B-Q8_0		Enacted cost containment measures including travel restrictions, temporary reductions in executive compensation, temporary suspension of matching contributions to certain benefit plans, and temporary work reductions for certain manufacturing teams due to COVID-19.
2020-03-31restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressEmployee Severance [Member] / Other Initiatives [Member]USD -2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressOther Restructuring [Member] / Other Initiatives [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressCR Bard Inc [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2020-03-31restructuringin_progressOther Initiatives [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-31restructuringin_progressC.R. Bard acquisition integrationUSD 17 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Quarter charge to expense covers employee termination ($4M) and other ($13M, largely converted pre-acquisition Bard equity awards); no headcount affected or completion date disclosed. Restructuring liability balance at 2019-12-31 was $20M (Bard).
2019-12-31restructuringin_progressPortfolio rationalization initiativesUSD 6 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Quarter charge to expense covers employee termination ($2M) and other ($4M); no headcount affected or completion date disclosed. Restructuring liability balance at 2019-12-31 was $24M (other initiatives).
2019-12-31restructuringin_progressUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to C.R. Bard acquisition integration. Employee termination costs of $4M and other costs of $13M recorded. No employee count disclosed.
2019-12-31restructuringin_progressUSD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges related to portfolio rationalization initiatives. Employee termination costs of $2M and other costs of $4M recorded. No employee count disclosed.
2019-12-31restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-31restructuringin_progressEmployee Severance [Member] / Other Initiatives [Member]USD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-31restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-31restructuringin_progressOther Restructuring [Member] / Other Initiatives [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-31restructuringin_progressCR Bard Inc [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-12-31restructuringin_progressOther Initiatives [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-09-30restructuringin_progressBard integrationUSD 23 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Fiscal 2019 employee-termination charges under the ongoing multi-year restructuring program begun with the Bard acquisition completed December 29, 2017. Total Bard restructuring charges in fiscal 2019 were $118 million, largely costs of converting pre-acquisition Bard equity awards to BD awards to encourage retention; no employee-affected count is disclosed. A $22 million employee-termination liability remained at September 30, 2019, indicating the program is ongoing. Companion record covers the 'Other Initiatives' program.
2019-09-30restructuringin_progressOther initiatives (CareFusion integration and portfolio rationalization)USD 29 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Fiscal 2019 employee-termination charges tied to the fiscal 2015 CareFusion acquisition and portfolio rationalization initiatives; no employee-affected count is disclosed. A $31 million employee-termination liability remained at September 30, 2019. Companion record covers the Bard-integration program.
2019-09-30restructuringin_progressUSD 180 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2019 restructuring charges of $180M relate to Bard integration plus CareFusion and portfolio rationalization initiatives; no employee-affected counts or completion dates disclosed
2019-09-30divestiture_reductioncompleted2018-092018-10Life Sciences (Biosciences unit — Advanced Bioprocessing)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of Advanced Bioprocessing business completed in October 2018 (Q1 FY2019); headcount removed not disclosed
2019-09-30restructuringcompletedGlobalMultiple segments (Medical, Life Sciences, Interventional)USD 180 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Total restructuring costs of $180 million recorded in 2019. Includes employee termination costs ($118 million) and other restructuring costs ($62 million). Primarily related to Bard acquisition integration and CareFusion portfolio rationalization. Employee count not explicitly disclosed in footnote.
2019-09-30acquisition_additioncompleted2017-12-29GlobalInterventional and Medicalbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Acquisition of C.R. Bard, Inc. completed December 29, 2017. Operating results included beginning January 1, 2018. Significant headcount added, but specific employee count not disclosed in this filing.
2019-09-30divestiture_reductioncompletedGlobalLife Sciencesdiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Sale of Advanced Bioprocessing business completed in October 2018. Headcount removed, but specific employee count not disclosed.
2019-09-30restructuringcompletedGlobalMultiple segments (Bard integration, CareFusion integration, portfolio rationalization)USD 180 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Includes employee termination and other costs related to Bard acquisition, CareFusion acquisition, and portfolio rationalization. Employee count not explicitly disclosed in footnote.
2019-09-30acquisition_additioncompleted2017-12-29GlobalMedical and Interventionalbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of C.R. Bard, Inc. completed Dec 29, 2017. Operating results included from Jan 1, 2018. Headcount added not explicitly quantified in this filing.
2019-09-30divestiture_reductioncompleted2018-10-01GlobalLife Sciences (Biosciences)discontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Sale of Advanced Bioprocessing business completed in October 2018. Headcount removed not explicitly quantified.
2019-09-30restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-09-30restructuringin_progressEmployee Severance [Member] / Other Initiatives [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-09-30restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 95,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-09-30restructuringin_progressOther Restructuring [Member] / Other Initiatives [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-09-30restructuringin_progressCR Bard Inc [Member]USD 118,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-09-30restructuringin_progressOther Initiatives [Member]USD 62,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2019-06-30restructuringin_progressUSD 27 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred largely in connection with the acquisition of Bard. Employee termination costs of $20 million and other costs of $13 million recorded for the nine months ended June 30, 2019. Employee count not disclosed.
2019-06-30restructuringin_progressUSD 99 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Total restructuring costs for the nine months ended June 30, 2019, including Bard integration and other initiatives. Employee count not disclosed.
2019-06-30restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressEmployee Severance [Member] / Other Initiatives [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 57,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressOther Restructuring [Member] / Other Initiatives [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressCR Bard Inc [Member]USD 69,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-06-30restructuringin_progressOther Initiatives [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressUSD 72 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring largely tied to the Bard acquisition; $72M charged to expense in the six months ended March 31, 2019 ($47M Bard, $25M other initiatives). No employee counts disclosed; severance liability balance was $43M at March 31, 2019.
2019-03-31divestiture_reductioncompleted2018-092018-10-31Life Sciences — Advanced Bioprocessingother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of the Advanced Bioprocessing business completed in October 2018; pre-tax gain of approximately $335 million recognized. No headcount associated with the divestiture was disclosed.
2019-03-31restructuringin_progressUSD 191 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred largely in connection with the acquisition of Bard. Includes employee termination costs and other restructuring costs.
2019-03-31divestiture_reductioncompletedLife Sciencesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of Advanced Bioprocessing business completed in October 2018. Headcount impact not quantified.
2019-03-31restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressEmployee Severance [Member] / Other Initiatives [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressOther Restructuring [Member] / Other Initiatives [Member]USD 17,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressCR Bard Inc [Member]USD 47,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2019-03-31restructuringin_progressOther Initiatives [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-31restructuringin_progressUSD 41 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred largely in connection with the acquisition of Bard. Includes $29M Bard and $12M CareFusion/Other Initiatives. Employee termination charges were $10M ($4M Bard, $6M CareFusion). Other restructuring charges were $31M ($25M Bard, $6M CareFusion). Employee count not disclosed.
2018-12-31divestiture_reductioncompleted2018-09-012018-10-31Life Sciencesbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of Advanced Bioprocessing business completed in October 2018. Pre-tax gain of $335M recognized. Employee count not disclosed.
2018-12-31restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-31restructuringin_progressEmployee Severance [Member] / CareFusion and Other Initiatives [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-31restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-31restructuringin_progressOther Restructuring [Member] / CareFusion and Other Initiatives [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-31restructuringin_progressCR Bard Inc [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-12-31restructuringin_progressCareFusion and Other Initiatives [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-09-30acquisition_additioncompleted2017-12-29Interventional (majority of Bard offerings); Medical (certain offerings, within Medication Delivery Solutions unit)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of C.R. Bard, Inc. completed December 29, 2017 for total consideration of approximately $25.0 billion; no acquired employee headcount disclosed. Bard operating results included in consolidated results beginning January 1, 2018; Bard contributed approximately $3 billion of fiscal 2018 revenues.
2018-09-30restructuringin_progress2017-12-29USD 136 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Employee termination costs charged to expense in fiscal 2018 in connection with the Bard acquisition. Cash payments of $103 million in FY2018; $33 million liability remained at September 30, 2018. Bard also incurred $156 million of other restructuring costs in FY2018 (equity award conversion, pension plan costs, offset by a gain on a product line sale). No affected-employee count disclosed.
2018-09-30restructuringin_progressUSD 30 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program (CareFusion integration and portfolio rationalization initiatives); only FY2018 activity captured. Employee termination charges of $30 million in fiscal 2018; cash payments of $56 million; $23 million liability remained at September 30, 2018. No affected-employee count disclosed.
2018-09-30divestiture_reductioncompleted2018-09discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Sale of Advanced Bioprocessing business completed October 2018, after fiscal year-end but before filing. Definitive agreement signed September 2018. Assets held for sale of $137 million at September 30, 2018; estimated gross proceeds approximately $475 million; business generated approximately $106 million of FY2018 revenues. No employee count disclosed.
2018-09-30acquisition_additioncompleted2017-12-29GlobalBD Interventional (majority of Bard products); BD Medical (remainder)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		C.R. Bard acquisition closed December 29, 2017; total consideration of approximately $25 billion. Bard operating results included from January 1, 2018. Headcount added through the acquisition is not disclosed.
2018-09-30acquisition_additioncompleted2018-07-31United StatesBD Interventional — vascular access / dialysisItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired in July 2018; described as not material to consolidated results. Employee count added not disclosed.
2018-09-30divestiture_reductioncompleted2018-04-30GlobalBD Medical — Respiratory Solutions (Vyaire Medical)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of remaining 49.9% interest in Vyaire Medical completed April 2018 for gross proceeds of approximately $435 million; headcount removed not disclosed. Exact completion day not stated.
2018-09-30divestiture_reductioncompleted2018-09-302018-10-31GlobalBD Life Sciences — Advanced Bioprocessingsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement signed September 2018; sale completed October 2018, after fiscal year end. Estimated gross cash proceeds of approximately $475 million; assets held for sale of $137 million at September 30, 2018. Announcement and completion dates are month-level only. Headcount removed not disclosed.
2018-09-30restructuringin_progressGlobalPrimarily BD Interventional / Bard-related integrationUSD 292 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fiscal 2018 expense charged to Acquisitions and other restructurings for Bard-related activity: $136M employee termination plus $156M other (equity award conversion and Bard pension costs, net of a gain on sale of the soft tissue core needle biopsy line). Employees affected not disclosed; program continues into fiscal 2019.
2018-09-30restructuringin_progressGlobalCareFusion integration and portfolio rationalizationUSD 52 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fiscal 2018 expense charged to Acquisitions and other restructurings: $30M employee termination plus $22M other. Employees affected not disclosed; multi-year program, fiscal 2018 activity only.
2018-09-30restructuringin_progress2017-12-29GlobalAll SegmentsUSD 344 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Restructuring costs of $344 million incurred in fiscal 2018 related to the acquisition of C.R. Bard, Inc. and other portfolio rationalization initiatives. Employee count not explicitly disclosed in this filing.
2018-09-30acquisition_additioncompleted2017-12-29GlobalBD Interventional, BD MedicalItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		BD completed acquisition of C.R. Bard, Inc. on December 29, 2017. Operating activities included in consolidated results beginning January 1, 2018. Specific headcount added not disclosed.
2018-09-30divestiture_reductioncompleted2018-10-01GlobalBD Life SciencesItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		BD completed sale of Advanced Bioprocessing business in October 2018. Specific headcount removed not disclosed.
2018-09-30divestiture_reductioncompleted2018-04-01GlobalBD MedicalItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		In April 2018, BD completed sale of remaining interest in Vyaire Medical. Specific headcount removed not disclosed.
2018-09-30restructuringin_progressGlobalMultiple segments (Bard integration, CareFusion integration, portfolio rationalization)USD 344 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Includes restructuring costs related to Bard acquisition, CareFusion acquisition, and other portfolio rationalization initiatives. Employee count not disclosed in provided text.
2018-09-30acquisition_additioncompleted2017-12-29GlobalInterventional and Medical segmentsMD&A
f5-10k / Qwen3.6-27B-Q8_0		BD completed acquisition of C.R. Bard. Operating activities included beginning Jan 1, 2018. Specific headcount added not disclosed in provided text.
2018-09-30divestiture_reductioncompleted2018-09-302018-10-31GlobalAdvanced BioprocessingMD&A
f5-10k / Qwen3.6-27B-Q8_0		BD completed sale of Advanced Bioprocessing business in October 2018. Specific headcount removed not disclosed in provided text.
2018-09-30divestiture_reductioncompleted2018-04-30GlobalRespiratory Solutions / Vyaire MedicalMD&A
f5-10k / Qwen3.6-27B-Q8_0		BD completed sale of remaining interest in Vyaire Medical in April 2018. Specific headcount removed not disclosed in provided text.
2018-09-30restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 136,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-09-30restructuringin_progressEmployee Severance [Member] / CareFusion and Other Initiatives [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-09-30restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 156,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-09-30restructuringin_progressOther Restructuring [Member] / CareFusion and Other Initiatives [Member]USD 22,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-09-30restructuringin_progressCR Bard Inc [Member]USD 292,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-09-30restructuringin_progressCareFusion and Other Initiatives [Member]USD 52,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2018-06-30acquisition_additioncompleted2017-12-292017-12-29United StatesBD Interventional; BD Medicalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of C.R. Bard completed 2017-12-29 for ~$25.0B total consideration; Bard results included from 2018-01-01. No headcount added through the acquisition is disclosed in this filing.
2018-06-30restructuringin_progressCompany-wide (Bard integration, CareFusion and portfolio rationalization initiatives)USD 604 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		YTD nine-month restructuring charge of $604M recorded in Acquisitions and other restructurings; includes employee termination accruals (Bard $244M and CareFusion/Other $44M charged to expense YTD). Number of employees affected is not disclosed.
2018-06-30restructuringin_progressUSD 126 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs charged to expense for Bard-related restructuring during the nine months ended June 30, 2018. Employee count not disclosed.
2018-06-30restructuringin_progressUSD 30 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs charged to expense for CareFusion/Other Initiatives restructuring during the nine months ended June 30, 2018. Employee count not disclosed.
2018-06-30restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 126,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressEmployee Severance [Member] / CareFusion and Other Initiatives [Member]USD 30,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 118,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressOther Restructuring [Member] / CareFusion and Other Initiatives [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressCR Bard Inc [Member]USD 244,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-06-30restructuringin_progressCareFusion and Other Initiatives [Member]USD 44,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31acquisition_additioncompleted2017-04-032017-12-29GlobalBD Interventional / BD Medicalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of C. R. Bard completed 2017-12-29 for ~$25B total consideration; Bard results included from 2018-01-01. No headcount added disclosed.
2018-03-31restructuringin_progressGlobalBD Medical / BD InterventionalUSD 255 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended 2018-03-31 restructuring costs of $255M (Bard $216M, CareFusion/Other $39M) recorded in Acquisitions and other restructurings; no employee counts disclosed.
2018-03-31restructuringin_progressBardUSD 216 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges include $161M for employee terminations and $55M for other costs related to the Bard acquisition.
2018-03-31restructuringin_progressCareFusion/Other InitiativesUSD 39 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges include $24M for employee terminations and $15M for other costs related to CareFusion and other portfolio rationalization initiatives.
2018-03-31restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 161,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressEmployee Severance [Member] / CareFusion and Other Initiatives [Member]USD 24,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 55,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressOther Restructuring [Member] / CareFusion and Other Initiatives [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressCR Bard Inc [Member]USD 216,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2018-03-31restructuringin_progressCareFusion and Other Initiatives [Member]USD 39,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31acquisition_additioncompleted2017-12-292017-12-29United StatesBD Interventional (new segment); BD Medicalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of C.R. Bard completed 2017-12-29 for ~$25B total consideration. Headcount added not disclosed. Bard operating results included beginning 2018-01-01.
2017-12-31restructuringin_progressNot specifiedBard-related restructuring (employee termination)USD 142 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employee termination charges of $142M charged to expense in Q1 FY2018; $117M balance at 2017-12-31. Number of employees affected not disclosed.
2017-12-31restructuringin_progressNot specifiedCareFusion/Other portfolio rationalization initiatives (employee termination)USD 9 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employee termination charges of $9M charged to expense in Q1 FY2018; $42M balance at 2017-12-31. Number of employees affected not disclosed.
2017-12-31restructuringin_progressNot specifiedBard-related restructuring (other — equity award conversion)USD 75 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Relates to conversion of certain pre-acquisition Bard equity awards to BD equity awards; $75M charged, fully non-cash settled in the quarter.
2017-12-31restructuringin_progressBardUSD 217 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring costs incurred in connection with the acquisition of Bard. Employee termination charges of $142 million and other charges of $75 million were recorded. Employee count affected not disclosed.
2017-12-31restructuringin_progressCareFusion/Other InitiativesUSD 19 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring costs incurred in connection with fiscal year 2015 acquisition of CareFusion and other portfolio rationalization initiatives. Employee termination charges of $9 million and other charges of $10 million were recorded. Employee count affected not disclosed.
2017-12-31restructuringin_progressEmployee Severance [Member] / CR Bard Inc [Member]USD 142,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31restructuringin_progressEmployee Severance [Member] / CareFusion and Other Initiatives [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31restructuringin_progressOther Restructuring [Member] / CR Bard Inc [Member]USD 75,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31restructuringin_progressOther Restructuring [Member] / CareFusion and Other Initiatives [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31restructuringin_progressCR Bard Inc [Member]USD 217,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-12-31restructuringin_progressCareFusion and Other Initiatives [Member]USD 19,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-09-30divestiture_reductioncompleted2016-03-312016-10-03GlobalBD Medical — Respiratory Solutionsdiscontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement signed March 2016; 50.1% controlling interest sold October 3, 2016, retaining 49.9% non-controlling interest. No headcount transferred disclosed; business not classified as discontinued operations.
2017-09-30acquisition_additioncompleted2017-04-032017-04-03IsraelBD Medical — Medication Management Solutions (infusion pumps)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of the remaining 60% of Caesarea Medical Electronics; BD previously held 40%. No headcount added disclosed.
2017-09-30acquisition_additionannounced2017-04-232017-12-31GlobalBD Medicalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of C.R. Bard, Inc. at ~$24 billion; expected to close in the fourth calendar quarter of 2017. Bard shareholders to own ~15% of combined company. No Bard headcount disclosed; termination outside date January 23, 2018 (April 23, 2018 if only competition approvals outstanding).
2017-09-30restructuringin_progressGlobalCompany-wide (CareFusion integration and portfolio rationalization)USD 85 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2017 restructuring expense of $85M (employee termination $27M, other $58M); cash payments $57M; liability balance $55M at year-end. Employees affected not disclosed. FY2017 integration costs of $237M and transaction costs of $39M recorded separately in Acquisitions and other restructurings.
2017-09-30restructuringcompletedGlobalVariousUSD 85 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Filing discloses $85 million in restructuring costs for fiscal year 2017 related to CareFusion integration and portfolio rationalization. Employee count not disclosed.
2017-09-30divestiture_reductioncompleted2016-03-012016-10-03GlobalMedical Segment - Respiratory SolutionsItem 1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		BD sold 50.1% of Respiratory Solutions business in Oct 2016. Employee count not disclosed.
2017-09-30restructuringcompletedGlobalVariousUSD 85 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Restructuring costs incurred in connection with CareFusion acquisition and portfolio rationalization initiatives. Employee termination costs were $27 million; other costs were $58 million. Specific headcount affected is not disclosed.
2017-09-30divestiture_reductioncompleted2016-03-012016-10-03GlobalMedicaldiscontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Sale of 50.1% controlling interest in Respiratory Solutions business to form Vyaire Medical. Headcount removed is not explicitly quantified in the filing.
2017-09-30restructuringin_progressUSD 85,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-09-30restructuringin_progressEmployee Severance [Member]USD 27,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-09-30restructuringin_progressOther Restructuring [Member]USD 58,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2017-06-30restructuringin_progressUSD 54 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring program tied to the fiscal 2015 CareFusion acquisition and portfolio rationalization; $54M charged to expense in the nine months ended June 30, 2017 (employee termination $3M, other $51M), with a $51M liability balance at quarter-end. No employee counts disclosed.
2017-06-30acquisition_additionannounced2017-04-232017-12-31other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pending acquisition of C.R. Bard, Inc. for approximately $24 billion; expected to close in the fourth calendar quarter of 2017. No headcount added disclosed.
2017-06-30divestiture_reductioncompleted2016-10-032016-10-03BD Medical — Respiratory Solutionsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of 50.1% controlling interest in Respiratory Solutions (October 2016, prior fiscal period); retained 49.9% non-controlling interest. Disclosed for context in this filing; no headcount reduction figure provided.
2017-06-30restructuringin_progressUSD 3 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs charged to expense for the three months ended June 30, 2017. Part of ongoing restructuring related to CareFusion acquisition and portfolio rationalization.
2017-06-30restructuringin_progressUSD 54 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Total restructuring costs charged to expense for the nine months ended June 30, 2017, including $3 million in employee terminations and $51 million in other costs.
2017-06-30restructuringin_progressUSD 54,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressEmployee Severance [Member]USD 3,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-06-30restructuringin_progressOther Restructuring [Member]USD 51,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressUSD 46 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring tied to the FY2015 CareFusion acquisition and portfolio rationalization; $46M charged to expense for the six months ended March 31, 2017 (employee termination $18M, other $29M); liability balance $58M at March 31, 2017. No employee counts, geographies, or completion dates disclosed.
2017-03-31acquisition_additionannounced2017-04-23subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire C.R. Bard, Inc. at $317.00 per share (~$24 billion); expected to close fall 2017. No headcount added disclosed; financing includes $15.7B committed bridge facility.
2017-03-31restructuringin_progressUSD 18 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs charged to expense for the six months ended March 31, 2017. Related to fiscal year 2015 acquisition of CareFusion and other portfolio rationalization initiatives. No specific headcount affected is disclosed.
2017-03-31restructuringin_progressUSD 46,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressEmployee Severance [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2017-03-31restructuringin_progressOther Restructuring [Member]USD 29,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-12-31restructuringin_progressUSD 35 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred in connection with fiscal year 2015 acquisition of CareFusion and other portfolio rationalization initiatives. Includes $9 million in employee termination costs and $26 million in other costs.
2016-12-31divestiture_reductioncompleted2016-10-03Medicalbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sold 50.1% controlling financial interest in Respiratory Solutions business to form a joint venture. Employee count not disclosed.
2016-12-31restructuringin_progressUSD 35,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-12-31restructuringin_progressEmployee Severance [Member]USD 9,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-12-31restructuringin_progressOther Restructuring [Member]USD 26,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-09-30restructuringin_progressGlobalMedical segment (CareFusion integration) and portfolio rationalizationUSD 526 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2016 charge of $526M comprises employee termination $81M, share-based compensation $39M and other $406M (including a $214M capitalized software impairment and $81M held-for-sale losses). No employee counts disclosed; program relates to CareFusion integration and portfolio rationalization.
2016-09-30restructuringin_progressGlobalInformation technology function (transition to outsourced, cloud-based model)USD 13 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2016 employee termination costs for the IT function transition; component of the $81M FY2016 employee termination line. Headcount not disclosed.
2016-09-30divestiture_reductioncompleted2016-03-012016-10-03GlobalBD Medical — Respiratory Solutionssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement signed March 2016 to sell 50.1% and form a joint venture; transaction closed October 3, 2016 (after fiscal year-end), with BD retaining a 49.9% non-controlling interest. Announcement month stated only as March 2016; no headcount disclosed.
2016-09-30restructuringcompletedGlobalMedical and Life SciencesUSD 526 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Total restructuring costs of $526 million recorded in fiscal 2016. Includes $40 million for CareFusion acquisition integration, $13 million for IT function transition employee terminations, and $214 million non-cash charge to impair capitalized internal-use software assets held for sale. Employee termination costs specifically totaled $81 million (charged to expense) plus $39 million share-based compensation, per Note 11 table.
2016-09-30acquisition_additioncompleted2015-03-17GlobalMedicalItem_1_Business
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		BD completed acquisition of CareFusion Corporation on March 17, 2015. CareFusion product lines included in Medical Segment. Specific headcount added not disclosed in this filing, but total employee count increased from 49,500 in FY2015 to 50,928 in FY2016.
2016-09-30restructuringcompletedGlobalInformation TechnologyUSD 214 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charge to impair capitalized internal-use software assets held for sale as a result of information technology function transformation efforts. Employee termination costs of $13 million also included in this category.
2016-09-30restructuringcompletedGlobalCareFusion IntegrationUSD 40 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Employee termination costs relating to the CareFusion acquisition.
2016-09-30divestiture_reductioncompleted2016-03-012016-10-03GlobalRespiratory SolutionsUSD 81 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Non-cash impairment charges relating to the disposition of certain non-core businesses, including the sale of a majority interest in the Respiratory Solutions business.
2016-09-30restructuringin_progressUSD 526,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-09-30restructuringin_progressShare Based Compensation [Member]USD 39,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-09-30restructuringin_progressEmployee Severance [Member]USD 81,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-09-30restructuringin_progressOther Restructuring [Member]USD 406,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2016-06-30restructuringin_progressUSD 53 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Employee termination liability roll-forward for nine months ended 2016-06-30: $62M opening balance, $53M charged to expense, $65M cash payments, $50M closing balance. Related to CareFusion acquisition integration and portfolio rationalization; no employee count or completion date disclosed.
2016-06-30divestiture_reductionin_progress2016-03-01BD Medical — Respiratory Solutionsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement signed March 2016 to sell 50.1% of Respiratory Solutions and form a JV (BD retains 49.9%); expected to close later in 2016 subject to regulatory approvals. Assets held for sale ~$614M, liabilities ~$195M. No headcount impact disclosed.
2016-06-30restructuringin_progressUSD 53 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs charged to expense for the nine months ended June 30, 2016. Part of CareFusion acquisition and portfolio rationalization initiatives.
2016-06-30restructuringin_progressUSD 33 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Share-based compensation costs charged to expense for the nine months ended June 30, 2016, related to restructuring activities.
2016-06-30restructuringin_progressUSD 113 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Other restructuring costs charged to expense for the nine months ended June 30, 2016. Includes non-cash charge of $28 million after-tax for sale of non-core asset.
2016-06-30restructuringin_progressUSD 199,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressShare Based Compensation [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressEmployee Severance [Member]USD 53,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-06-30restructuringin_progressOther Restructuring [Member]USD 113,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressUSD 149 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring in connection with CareFusion acquisition and portfolio rationalization; $149M charged to expense in six months ended 2016-03-31 (employee termination $33M, share-based compensation $25M, other $91M). No employee headcount disclosed.
2016-03-31divestiture_reductionannounced2016-03-01GlobalBD Medical — Respiratory Solutionsother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement signed in March 2016 to sell 50.1% of Respiratory Solutions and form a JV; BD retains 49.9% non-controlling interest. Assets held for sale ~$588M, liabilities ~$202M. Expected to close later in 2016. No employee headcount disclosed.
2016-03-31acquisition_additioncompleted2015-03-172015-03-17GlobalBD Medicalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		CareFusion acquisition closed 2015-03-17; operating results included from 2015-04-01. CareFusion contributed $1.017B revenue in Q2 FY2016. No headcount added disclosed.
2016-03-31restructuringin_progressUSD 33 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs charged to expense for the six months ended March 31, 2016. Part of CareFusion acquisition and portfolio rationalization initiatives.
2016-03-31restructuringin_progressUSD 25 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Share-based compensation costs charged to expense for the six months ended March 31, 2016, related to restructuring activities.
2016-03-31restructuringin_progressUSD 91 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Other restructuring costs charged to expense for the six months ended March 31, 2016. Includes non-cash charge of $28 million after-tax for sale of non-core asset.
2016-03-31restructuringin_progressUSD 149,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressShare Based Compensation [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressEmployee Severance [Member]USD 33,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2016-03-31restructuringin_progressOther Restructuring [Member]USD 91,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-12-31restructuringin_progressUSD 85 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program tied to CareFusion integration and portfolio rationalization; $85M charged to expense in the quarter comprises $11M employee termination, $15M share-based compensation, and $59M other. Severance liability ended the quarter at $52M. No employee counts, geographies, or completion dates disclosed. Note 8 separately cites $3M of CareFusion-related employee termination charges in the quarter.
2015-12-31divestiture_reductionannounced2015-12USD 28 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement reached in December 2015 to sell a non-core asset, driving a non-cash after-tax charge of $28M within the restructuring 'Other' column. No headcount impact disclosed.
2015-12-31restructuringin_progressUSD 85 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring costs incurred in connection with the CareFusion acquisition and portfolio rationalization. Includes $11M employee termination, $15M share-based compensation, and $59M other (primarily $28M non-cash charge for sale of non-core asset). Employee count not disclosed.
2015-12-31restructuringin_progressUSD 85,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-12-31restructuringin_progressShare Based Compensation [Member]USD 15,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-12-31restructuringin_progressEmployee Severance [Member]USD 11,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-12-31restructuringin_progressOther Restructuring [Member]USD 59,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-09-30acquisition_additioncompleted2014-10-052015-03-17GlobalBD Medicalbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquired 100% of CareFusion on March 17, 2015 for total consideration of $12.538 billion; results consolidated beginning April 1, 2015. CareFusion employee headcount not disclosed. Item 6 Selected Financial Data shows number of employees of 49,500 for FY2015 versus 30,600 for FY2014.
2015-09-30restructuringin_progress2014-10-052016-09-30GlobalBD MedicalUSD 271 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Restructuring incurred throughout FY2015 in connection with the CareFusion acquisition. FY2015 components: employee termination $126 million, share-based compensation $44 million, other $102 million (including $72 million impairment of assets held for sale tied to an IT infrastructure outsourcing project planned for FY2016). Accrual balance of $62 million at September 30, 2015; integration costs expected to continue through fiscal 2016. Employees affected not disclosed.
2015-09-30acquisition_additioncompletedIrelandBD Life Sciencesbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		GenCell Biosystems, an Irish biotechnology company (next-generation sequencing library preparation and genotyping), completed during the first quarter of fiscal 2015. Headcount not disclosed; goodwill allocated to Life Sciences segment per Note 6.
2015-09-30acquisition_additioncompleted2015-03United StatesBD Medicalbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		CRISI Medical Systems, a San Diego-based medical technology company focused on IV injectable medication safety, fully acquired in March 2015 (second quarter of fiscal 2015). Headcount not disclosed; goodwill allocated to Medical segment per Note 6.
2015-09-30acquisition_additioncompletedWestern EuropeBD Medicalbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		ARX group of companies, a leading pharmacy automation distributor in Western Europe, completed during the third quarter of fiscal 2015. Headcount not disclosed; goodwill allocated to Medical segment per Note 6.
2015-09-30acquisition_additioncompletedBD Life Sciencesbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Cellular Research, Inc., a biotechnology R&D company (single-cell genetic analysis via Molecular Indexing technology), completed during the fourth quarter of fiscal 2015. Headcount not disclosed; goodwill allocated to Life Sciences segment per Note 6.
2015-09-30acquisition_additioncompleted2014-10-052015-03-17United StatesBD Medicalbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		CareFusion acquired 100% on March 17, 2015 for $12.538 billion consideration; acquired headcount is not separately disclosed. CareFusion operating results included from April 1, 2015.
2015-09-30restructuringin_progress2015-03-17GlobalBD Medical (CareFusion integration)USD 271 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2015 restructuring costs charged to Acquisition-related costs: $126M employee termination, $44M share-based compensation, $102M other (primarily asset impairments for an IT infrastructure outsourcing project). $62M accrual balance at year-end; employees affected not disclosed. Integration costs of $95M and transaction costs of $59M reported separately in Acquisition-related costs.
2015-09-30otherin_progress2015-03-17United StatesInfusion pumps (Medication Management Solutions)Item_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		CareFusion's amended 2009 FDA consent decree applies to infusion pumps; no accrual recorded at September 30, 2015 and no workforce impact quantified.
2015-09-30restructuringcompleted2015-03-17GlobalMedical (CareFusion Acquisition)USD 271 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Costs incurred in connection with the CareFusion acquisition. Includes employee termination costs, share-based compensation, asset write-offs and other restructuring costs. Employee termination costs charged to expense were $126 million. Cash payments for employee termination were $74 million. Remaining liability at Sept 30, 2015 was $62 million.
2015-09-30restructuringcompleted2014-10-01GlobalLegacy BDUSD -5 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Adjustment to decrease liability for employee termination costs recorded relative to workforce reduction actions taken in the fourth quarter of fiscal year 2014. The 2014 charge was $36 million.
2015-09-30restructuringin_progress2015-03-17GlobalMedical (CareFusion Integration)USD 271 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Restructuring costs incurred in connection with the CareFusion acquisition. Includes $126 million in employee termination costs, $44 million in share-based compensation, and $102 million in other costs. Employee count not explicitly disclosed in the footnote.
2015-09-30acquisition_additioncompleted2015-03-17GlobalMedicalbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of CareFusion Corporation. Headcount added is not explicitly disclosed, but total employees increased from 30,600 in FY2014 to 49,517 in FY2015.
2015-09-30restructuringin_progressUSD 271,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-30restructuringin_progressCare Fusion Corporation [Member]USD 271,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-30restructuringin_progressShare Based Compensation [Member]USD 44,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-30restructuringin_progressEmployee Severance [Member]USD 126,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-09-30restructuringin_progressOther Restructuring [Member]USD 102,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2015-06-30acquisition_additioncompleted2014-10-052015-03-17GlobalBD Medicalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		CareFusion acquired 100% on 2015-03-17 for $12.538 billion total consideration; headcount added through the acquisition is not disclosed. CareFusion operating results included in consolidated results beginning 2015-04-01.
2015-06-30restructuringin_progressNot specifiedBD Medical (CareFusion integration)USD 136 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring in connection with the CareFusion acquisition; $136 million charged to expense for the nine months ended 2015-06-30 (employee termination $87M, share-based compensation $37M, other $12M), including a $19M assumed liability. Number of employees affected not disclosed. Company expects to continue incurring substantial integration costs through fiscal 2016.
2015-06-30restructuringin_progressUnited StatesCorporate (workforce reductions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Residual liability of $9 million as of 2015-06-30 relating to broad workforce reduction actions taken in Q4 fiscal 2014 ($36 million charge); liability decreased $5 million on change in estimate during the quarter. Headcount affected not disclosed; program predates the current fiscal year.
2015-06-30restructuringin_progress2015-03-17GlobalMedicalUSD 136 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring costs incurred in connection with the CareFusion acquisition. Includes employee termination costs ($87M), share-based compensation ($37M), and other ($12M) charged to expense for the nine months ended June 30, 2015. Employee headcount affected is not disclosed.
2015-06-30restructuringcompleted2014-10-01GlobalOtherUSD -5 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Adjustment to decrease liability for employee termination costs recorded relative to workforce reduction actions taken in the fourth quarter of fiscal year 2014. Reflects payments and a change in estimate.
2015-06-30restructuringin_progressCare Fusion Corporation [Member] / Employee Severance [Member]USD 87,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressCare Fusion Corporation [Member] / Other Restructuring [Member]USD 12,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressCare Fusion Corporation [Member] / Share Based Compensation [Member]USD 37,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-06-30restructuringin_progressCare Fusion Corporation [Member]USD 136,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31acquisition_additioncompleted2014-10-052015-03-17GlobalBD Medicalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		CareFusion Corporation acquired 100% on 2015-03-17 for total consideration of $12.538 billion; headcount added not disclosed. All acquired assets allocated to Medical segment.
2015-03-31restructuringin_progress2014-10-05GlobalBD Medical (CareFusion integration)USD 62 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring costs of $62M in Q2 FY2015, comprising $34M employee termination costs, $18M accelerated share-based compensation, and $10M other. Employee headcount affected not disclosed. Remaining liability for termination actions was $4M at 2015-03-31.
2015-03-31restructuringin_progressUnited StatesCorporate / workforce reductionUSD 36 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge recognized in Q4 FY2014 for broad workforce reduction actions; remaining liability of $17M at 2015-03-31. Employee count affected not disclosed in this filing.
2015-03-31restructuringin_progress2015-03-31USD 34 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Employee termination costs recognized in connection with the acquisition of CareFusion. Remaining liability of $4 million at March 31, 2015.
2015-03-31restructuringin_progress2014-09-30restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Workforce reduction actions from Q4 FY2014. Remaining liability of $17 million at March 31, 2015.
2015-03-31restructuringin_progressCare Fusion Corporation [Member] / Corporate, Non-Segment [Member]USD 62,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressCare Fusion Corporation [Member]USD 62,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressCare Fusion Corporation [Member] / Other Restructuring [Member]USD 10,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressCare Fusion Corporation [Member] / Employee Severance [Member]USD 34,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2015-03-31restructuringin_progressCare Fusion Corporation [Member] / Share Based Compensation Related [Member]USD 18,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2014-12-31acquisition_additioncompletedIrelandLife Sciencesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		GenCell Biosystems acquired during Q1 FY2015; $80M in-process R&D recognized and $64M goodwill added to Life Sciences segment. No employee headcount disclosed.
2014-12-31acquisition_additionannounced2014-10-052015-06-30United StatesMedicalUSD 23 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		CareFusion acquisition pending; $12.2B deal announced 2014-10-05, expected to close by end of Q2 FY2015. $23M integration and transaction costs incurred in Q1 FY2015. No employee headcount disclosed.
2014-12-31restructuringcompleted2015-06-30USD 36 (millions)other
f5-10q / Qwen3.6-27B-Q8_0		Charge associated with unusually broad and significant workforce reduction actions. Remaining liability of $24 million expected to be paid by end of Q2 FY2015.
2014-09-30reduction_in_forcein_progress20142015-03-31Medical segmentUSD 21 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		FY2014 workforce reduction actions initiated in fiscal Q4 2014; no employee headcount affected was disclosed. Part of single $36M pre-tax employee termination cost program allocated by segment in Note 6 (Medical $21M, Diagnostics $5M, Biosciences $5M, corporate $5M). Note 8 (Postemployment) states all costs expected incurred by end of Q2 fiscal 2015 (ending 2015-03-31).
2014-09-30reduction_in_forcein_progress20142015-03-31Diagnostics segmentUSD 5 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Segment allocation of the same FY2014 workforce reduction program (fiscal Q4 initiation); headcount affected not disclosed. Program total $36M; all costs expected incurred by end of Q2 fiscal 2015.
2014-09-30reduction_in_forcein_progress20142015-03-31Biosciences segmentUSD 5 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Segment allocation of the same FY2014 workforce reduction program (fiscal Q4 initiation); headcount affected not disclosed. Program total $36M; all costs expected incurred by end of Q2 fiscal 2015.
2014-09-30reduction_in_forcein_progress20142015-03-31Corporate functionsUSD 5 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Corporate-function allocation of the same FY2014 workforce reduction program (fiscal Q4 initiation); headcount affected not disclosed. Program total $36M; all costs expected incurred by end of Q2 fiscal 2015.
2014-09-30restructuringin_progress2015-03-31GlobalCompany-wide (charge portions: Medical $21M, Diagnostics $5M, Biosciences $5M, corporate $5M)USD 36 (millions)MD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Workforce reduction actions initiated in Q4 FY2014 affecting a significant number of employees; no headcount disclosed. All related costs expected to be incurred by the end of Q2 FY2015.
2014-09-30acquisition_additioncompletedUnited StatesBD Diagnosticsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Alverix, Inc. acquired in Q2 FY2014 for approximately $40 million cash; acquired headcount not disclosed.
2014-09-30acquisition_additionannounced2014-10-03IrelandBD Biosciences (life sciences/genomics)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Post-fiscal-year-end acquisition of privately held Irish biotech GenCell Biosystems; headcount not disclosed.
2014-09-30acquisition_additionannounced2014-10-052015-06-30United StatesBD Medical (medication management and patient safety)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger agreement announced October 5, 2014 for approximately $12.2 billion; expected to close in first half of calendar 2015. CareFusion headcount not disclosed; integration-related workforce actions not quantified.
2014-09-30restructuringcompleted2014-09-302015-06-30GlobalAll SegmentsUSD 36 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Workforce reduction actions initiated in Q4 2014 affecting a significant number of employees. Pre-tax charge of $36 million. All costs expected to be incurred by end of Q2 2015.
2014-09-30restructuringcompleted2014-09-302015-06-30GlobalAll SegmentsUSD 36 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Workforce reduction actions initiated in fiscal 2014 affecting a significant number of employees. Pre-tax charge of $36 million for employee termination costs. All costs expected to be incurred by end of Q2 FY2015.
2014-03-31acquisition_additioncompletedUnited StatesBD DiagnosticsUSD 40 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Alverix, Inc. in Q2 FY2014; $40M net cash outflow disclosed in cash flow statement. No employee count disclosed.
2014-03-31divestiture_reductioncompleted2012-10-312012-10-31GlobalBD Biosciences — Discovery Labware unitother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Discovery Labware unit completed October 31, 2012; disclosed as discontinued operations. No employee count disclosed. Prior-period event retained for context only.
2013-12-31acquisition_additionannounced2014-01-062014-01-06United StatesBD DiagnosticsUSD 40 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of Alverix, Inc., a privately held diagnostic instrument company, for $40 million to expand point-of-care testing position; no headcount disclosed.
2013-09-30divestiture_reductioncompleted2012-10-31BD Biosciences — Discovery Labware unit (excluding Advanced Bioprocessing platform)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Sale to Corning Incorporated closed October 31, 2012 (fiscal 2013 first quarter); date shown is the completion date. Gross proceeds were approximately $740 million with a $577 million pre-tax gain recorded in discontinued operations. Number of employees transferred or removed was not disclosed. Also referenced in Item 1 and MD&A; footnote used as the authoritative source.
2013-09-30acquisition_additioncompleted2012-12-24United States (California-based company)BD MedicalUSD 124 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Safety Syringes, Inc., a developer of anti-needlestick devices for prefilled syringes, closed December 24, 2012 (fiscal 2013 Q1); date shown is the acquisition date. Value is fair value of consideration transferred net of cash acquired — not a severance or restructuring charge. Headcount added through the acquisition was not disclosed.
2013-09-30acquisition_additioncompleted2013-03-11AustriaBD MedicalUSD 23 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Acquisition of Cato Software Solutions, a medication safety software maker, closed March 11, 2013 (fiscal 2013 Q2); date shown is the acquisition date. Value comprises $14 million cash (net of cash acquired) plus $9 million contingent consideration — not a severance or restructuring charge. Headcount added through the acquisition was not disclosed.
2013-09-30acquisition_additioncompleted2012-12-24United States (California)BD Medical — Pharmaceutical SystemsUSD 124 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired 100% of Safety Syringes, Inc. for $124 million net of cash acquired; no headcount of acquired employees disclosed. Consideration is purchase price, not a severance charge.
2013-09-30acquisition_additioncompleted2013-03-11AustriaBD MedicalUSD 23 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired 100% of Cato Software Solutions for $23 million ($14 million cash plus $9 million contingent consideration); no acquired headcount disclosed. Consideration is purchase price, not a severance charge.
2013-09-30divestiture_reductioncompleted2012-10-312012-10-31Not disclosedBD Biosciences — Discovery Labware unit (excluding Advanced Bioprocessing)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale to Corning Incorporated completed October 31, 2012 (fiscal 2013 first quarter) for approximately $740 million gross proceeds; no headcount removed disclosed. Company agreed to provide contract manufacturing and transition services for a defined period post-sale.
2012-12-31divestiture_reductioncompleted2012-10-31BD Biosciences — Discovery Labware unit (excluding Advanced Bioprocessing)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of Discovery Labware to Corning completed 2012-10-31; no employee count disclosed in filing.
2012-12-31acquisition_additioncompleted2012-12-24United States (California)BD Medicalbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Safety Syringes, Inc. closed 2012-12-24; no employee count disclosed in filing.
2012-12-31acquisition_additioncompleted2012-12-24CaliforniaMedicalUSD 124 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquired 100% interest in Safety Syringes, Inc. Headcount not disclosed.
2012-12-31divestiture_reductioncompleted2012-10-31BiosciencesUSD 724 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sold BD Biosciences Discovery Labware unit. Headcount not disclosed.
2012-09-30acquisition_additioncompleted2012-02-092012-02-09NetherlandsBD Diagnosticsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Fair value of consideration transferred was $59.5 million ($51 million cash net of cash acquired plus $8 million contingent consideration). Headcount added through the acquisition is not disclosed.
2012-09-30acquisition_additioncompleted2012-08-242012-08-24BD Biosciencesbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Fair value of consideration transferred was $64.4 million ($52 million cash net of cash acquired plus $12 million contingent consideration). Headcount added through the acquisition is not disclosed.
2012-09-30divestiture_reductioncompleted2012-04-102012-10-31BD Biosciences — Discovery Labware unit (excluding Advanced Bioprocessing platform)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Definitive agreement with Corning Incorporated signed April 10, 2012; sale completed October 31, 2012, after fiscal year-end. Gross cash proceeds approximately $728 million, subject to post-closing adjustments. Headcount removed through the divestiture is not disclosed.
2012-09-30acquisition_additionannounced2012-06-292012-12-31California, United StatesAnti-needlestick devices for prefilled syringes (Safety Syringes, Inc.)MD&A
f5-10k / GLM-5.3-flash-HTML		Definitive agreement to acquire privately held Safety Syringes, Inc., subject to customary closing conditions including regulatory approvals; expected to close by the end of the Company's first fiscal quarter of 2013 (quarter ending December 31, 2012). Headcount not disclosed.
2012-09-30acquisition_additioncompleted2012-02-092012-02-09NetherlandsBD DiagnosticsUSD 59 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		100% interest in KIESTRA Lab Automation BV acquired for $59M fair value consideration; no headcount disclosed.
2012-09-30acquisition_additioncompleted2012-08-242012-08-24United KingdomBD BiosciencesUSD 64 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		100% interest in Sirigen Group Limited acquired for $64M fair value consideration; no headcount disclosed.
2012-09-30acquisition_additionannounced2012-06-292012-12-31United StatesBD MedicalMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Safety Syringes, Inc.; expected to close by end of first fiscal quarter of 2013, subject to closing conditions; no headcount disclosed.
2012-09-30divestiture_reductioncompleted2012-04-102012-10-31GlobalBD Biosciences — Discovery Labware unit (excluding Advanced Bioprocessing)USD 728 (millions)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale to Corning completed 2012-10-31 (after fiscal year-end, before filing) for approximately $728M gross proceeds; no headcount disclosed.
2012-06-30acquisition_additioncompleted2012-02-09NetherlandsBD Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of KIESTRA Lab Automation BV closed February 9, 2012; consideration $59,457 thousand ($50,891 thousand cash net of cash acquired plus $8,566 thousand contingent consideration). No employee headcount added disclosed.
2012-06-30divestiture_reductionannounced2012-04-102012-12-31GlobalBD Biosciences — Discovery Labware unit (excluding Advanced Bioprocessing)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to sell Discovery Labware signed April 10, 2012; gross cash proceeds expected approximately $730,000 thousand; results reclassified to discontinued operations. No employee headcount reduction disclosed; assets held for sale of $131,591 thousand at June 30, 2012.
2012-06-30acquisition_additionannounced2012-06-292012-09-30United StatesBD Medical — prefilled syringe safety devicessubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Safety Syringes, Inc. entered June 29, 2012, subject to customary closing conditions including regulatory approvals; expected to close by end of fiscal year 2012. No employee headcount disclosed.
2012-03-31acquisition_additioncompleted2012-02-09NetherlandsBD Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		100% interest acquired; headcount added not disclosed. $2,500 thousand acquisition-related costs expensed in S&A.
2012-03-31divestiture_reductionannounced2012-04-102012-12-31GlobalBD Biosciences — Discovery Labware (excluding Advanced Bioprocessing)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to sell signed after quarter end; expected cash proceeds ~$730,000 thousand; headcount reduction not disclosed.
2011-09-30acquisition_additioncompleted2011-03-172011-03-17United StatesBD BiosciencesUSD 205 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Accuri Cytometers, Inc. for $204,970 thousand net of cash acquired; headcount added not disclosed.
2011-09-30acquisition_additioncompleted2011-09-302011-09-30SwedenBD MedicalUSD 287 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Fourth-quarter acquisition of Carmel Pharma AB for $287,111 thousand net of cash acquired; exact announcement/completion date not specified beyond fiscal Q4 2011; headcount added not disclosed.
2011-03-31acquisition_additioncompleted2011-03-18United States (Ann Arbor, Michigan)BD Biosciencesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of Accuri Cytometers, Inc.; consideration $204,970 thousand net of cash acquired. Headcount added through the acquisition is not disclosed; $900 thousand of acquisition-related costs expensed in S&A.
2010-12-31divestiture_reductioncompletedBD Medical (Ophthalmic Systems unit; surgical blades, critical care and extended dwell catheter product platforms)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sold in the fourth quarter of fiscal 2010 (quarter ended 2010-12-31) for $270,000 thousand with a pre-tax gain of $140,468 thousand; no employee counts disclosed. Results reported as discontinued operations.
2010-12-31acquisition_additionannounced2011-02-04United States (Ann Arbor, Michigan)BD Biosciences (personal flow cytometers)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire Accuri Cytometers, Inc. signed after quarter end; expected to close in Q3 fiscal 2011 subject to regulatory approvals. No headcount disclosed.
2010-09-30acquisition_additioncompleted2009-11-192009-11-19United StatesBD DiagnosticsUSD 275 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price of $275 million cash ($277.6 million consideration net of cash acquired); acquired headcount is not disclosed. Consideration is the acquisition price, not a severance or restructuring charge.
2010-09-30divestiture_reductioncompleted2010-05-012010-09-30Not disclosedBD Medical (Medical Surgical Systems)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreements signed in May 2010 to sell the Ophthalmic Systems unit plus the surgical blades, critical care and extended dwell catheter platforms for $270 million; Ophthalmic Systems and surgical blades closed 2010-07-30, critical care and extended dwell closed 2010-09-30. Pre-tax gain of $139.2 million recognized; affected headcount not disclosed. Announcement month stated only as May 2010.
2009-12-31acquisition_additioncompleted2009-11-19United StatesBD Diagnosticsbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of HandyLab, Inc. (molecular diagnostics assays and automation platforms) for $277.6 million net of cash acquired; no employee headcount added disclosed. $2.5 million of acquisition-related costs expensed in the quarter.
2009-09-30divestiture_reductioncompleted2009-07-082009-07-08Medical segment — Home Healthcare product line (elastics and thermometer components)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Elastics and thermometer assets sold for $51.0 million with an $18.1 million pre-tax gain, and the remaining Home Healthcare line exited concurrently; results reported as discontinued operations. Headcount removed not disclosed. Sale proceeds are transaction consideration, not a workforce charge, so associated_charge fields are null.
2009-09-30acquisition_additioncompleted2009-11-192009-11-19Diagnostics — molecular diagnostics (healthcare-associated infections)subsequent_events
f5-10k / GLM-5.3-flash-HTML		Acquired 100% of HandyLab, Inc. for $275 million in cash after fiscal year-end but before filing; purchase accounting incomplete at filing. Headcount added not disclosed. Purchase price is transaction consideration, not a workforce charge, so associated_charge fields are null.
2009-09-30divestiture_reductioncompleted2009-07-082009-07-08United StatesBD Medical — Home Healthcare product line (elastics and thermometer components)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sold for $51.0 million with a pre-tax gain of $18.1 million; concurrent exit from the remaining Home Healthcare line. Headcount not disclosed.
2009-09-30acquisition_additioncompleted2009-11-192009-11-19United StatesBD Diagnostics — molecular diagnosticsUSD 275 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price in cash for HandyLab, Inc.; occurred after fiscal year-end and before filing date. Headcount added not disclosed.
2009-09-30acquisition_additioncompleted2009-11-19GlobalBD DiagnosticsUSD 275 (millions)Item 1. Business - Acquisitions
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		BD acquired 100% of HandyLab on November 19, 2009, for $275 million in cash. Employee count not disclosed.
2008-09-30acquisition_additioncompleted2008-05-122008-05-12United StatesBD Biosciencesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		100% of Cytopeia Inc. acquired May 12, 2008 for $42,914 thousand cash; purchase price allocation disclosed but no employee headcount added is stated.
2008-06-30acquisition_additioncompleted2008-05-12United States (Seattle, Washington)BD Biosciencesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of 100% of Cytopeia Inc. stock for $43,049 thousand cash; headcount added not disclosed. Results included in Biosciences from acquisition date.
2007-09-30acquisition_additioncompleted2006-12-202006-12-20BD DiagnosticsUSD 114,739 (thousands)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired remaining ~93.8% of TriPath Imaging; charge is non-deductible acquired in-process R&D. No headcount added is disclosed.
2007-09-30acquisition_additioncompleted2007-05-042007-05-04BD BiosciencesUSD 7,394 (thousands)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired all shares of Plasso Technology, Ltd.; accounted for as asset acquisition. No headcount added is disclosed.
2007-09-30divestiture_reductioncompleted2006-09-282006-12-11BD Medical — Diabetes Care (blood glucose monitoring)USD 63,414 (thousands)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Exit announced September 28, 2006 (charge recorded in FY2006); product line sold December 11, 2006 for $19,971 thousand. Severance and exit costs included in the charge; affected-employee count not disclosed.
2007-09-30divestiture_reductioncompleted2006-09-282006-12-11GlobalBlood Glucose Monitoring (BGM)USD 63 (thousands)discontinued_operations_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Company announced plan to exit BGM market in Sept 2006 and sold product line in Dec 2006. Pre-tax charge of $63.4 million recorded in 2006 included $12.4 million for severance and other exit costs. Employee count not explicitly disclosed.
2007-09-30restructuringcompleted2006-09-282007-12-31GlobalBlood Glucose Monitoring (BGM)USD 63 (thousands)discontinued_operations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Plan to exit BGM market announced Sept 2006. Charge of $63.4M included $12.4M for severance and other exit costs. Product line sold in Dec 2006.
2007-06-30acquisition_additioncompleted2007-05-04United KingdomBD BiosciencesUSD 7 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired all outstanding shares of Plasso Technology, Ltd. for $10.425 million cash; charge relates to acquired in-process R&D, not severance. No employee headcount added disclosed.
2007-06-30divestiture_reductioncompleted2006-09-282006-12-11MedicalUSD 63,414 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Company exited blood glucose monitoring (BGM) market. Pre-tax charge of $63.4 million recorded in Medical segment. Product line sold for $20 million on Dec 11, 2006. Employee count not disclosed.
2007-03-31divestiture_reductioncompleted2006-09-282006-12-11MedicalUSD 63,414 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Exit from blood glucose monitoring market; pre-tax charge of $63.4 million recorded in Medical segment. Product line sold for $20 million.
2006-12-31acquisition_additioncompleted2006-12-202006-12-20BD DiagnosticsUSD 115 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired ~93.8% of TriPath Imaging for $361.9M cash; non-deductible in-process R&D charge of $114.7M recorded. No employee headcount added disclosed.
2006-12-31divestiture_reductioncompleted2006-09-282006-12-11BD Medical (Blood Glucose Monitoring product line)USD 63 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sold BGM product line for $19.971M with $15.226M pre-tax gain; $63.4M exit charge recorded in prior quarter. No employee headcount reduction disclosed; remaining exit-cost accrual of $14.558M at quarter end.
2006-12-31restructuringin_progress2006-09-28MedicalUSD 63,414 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Pre-tax charge for exit from blood glucose monitoring market; accrual included inventory commitments and severance.
2006-12-31divestiture_reductioncompleted2006-12-112006-12-11Medicalbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Sale of blood glucose monitoring product line; results presented as discontinued operations.
2006-09-30restructuringin_progress2006-09-282007-12-31Medical segment — Diabetes Care (blood glucose monitoring product line)USD 12 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Decision to exit the BGM market: BD Logic meter distribution discontinued immediately at announcement; test strips to be distributed through December 2007. Total pre-tax exit charge was $63.4M, comprising $12.4M of severance and other exit costs, $31.6M of inventory/purchase-commitment write-offs, $14.1M of long-lived asset write-downs and $5.4M of estimated sales returns; $32.4M was accrued in current liabilities at September 30, 2006. Affected-employee headcount not disclosed.
2006-09-30restructuringin_progress2006-09-282007-12-31WorldwideBD Medical — Diabetes Care (blood glucose monitoring)USD 12 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Exit from the blood glucose monitoring market; total pre-tax charge of $63.4 million including $5.4M sales returns, $31.6M inventory/purchase commitments, $14.1M long-lived asset write-downs and $12.4M severance/exit costs. Test strip distribution continues through December 2007; headcount affected not disclosed.
2006-09-30acquisition_additioncompleted2006-02-142006-02-14United StatesBD DiagnosticsUSD 53 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of GeneOhm Sciences, Inc.; charge is acquired in-process research and development, not severance. Headcount added not disclosed.
2006-09-30acquisition_additionannounced2006-09-082006-12-31United StatesBD DiagnosticsItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire the 93.5% of TriPath Imaging not already owned, at $9.25 per share (~$350 million); expected to close by the end of fiscal first quarter 2007. Headcount added not disclosed.
2006-09-30acquisition_additioncompleted2006-02-14GlobalBD DiagnosticsUSD 233 (thousands)Item 1. Business - Acquisitions
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		BD acquired GeneOhm Sciences, Inc. on February 14, 2006. Specific headcount added is not disclosed.
2006-09-30restructuringcompleted2006-09-282007-12-31GlobalBD MedicalUSD 63 (thousands)Item 1. Business - Exit from Blood Glucose Monitoring Market
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		BD announced a plan to exit the blood glucose monitoring market and discontinued distribution of the BD Logic Blood Glucose Monitor. Test strips will continue to be distributed through December 2007. Specific headcount affected is not disclosed.
2006-09-30restructuringannounced2006-09-282007-12-31WorldwideBD Medical - Diabetes CareUSD 63 (millions)Item_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Announced plan to exit blood glucose monitoring market; discontinued distribution of BD Logic Blood Glucose Monitor. Plans to continue distributing test strips through December 2007. Pre-tax charge of $63 million recorded.
2006-09-30acquisition_additioncompleted2006-02-142006-02-14United StatesBD DiagnosticsItem_1_Business
f5-10k / Qwen3.6-27B-Q8_0		Acquired GeneOhm Sciences, Inc. on February 14, 2006. Headcount not explicitly disclosed.
2006-06-30acquisition_additioncompleted2006-02-14United StatesBD DiagnosticsUSD 53 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition closed 2006-02-14; $53.3M non-deductible in-process R&D charge recorded in R&D expense. No headcount added by the acquisition is disclosed.
2005-09-30divestiture_reductioncompleted2005-08-31BD Biosciences — Clontech unitdiscontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Sale of the Clontech unit completed August 31, 2005 for $62.1 million, with a pre-tax gain of $13.3 million ($28.5 million after taxes). Headcount of the divested unit was not disclosed; the ~$124 million net-asset write-down was recorded in fiscal 2004, not the current year.
2005-09-30divestiture_reductioncompleted2005-08-31GlobalBD Biosciences (Clontech unit)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of the Clontech unit completed August 31, 2005 for $62.1 million; no headcount associated with the divestiture is disclosed.
2005-09-30divestiture_reductioncompleted2005-08-31GlobalBD Biosciences (Clontech unit)Item 1. Business - Discontinued Operations
f5-10k / Qwen3.6-27B-Q8_0		On August 31, 2005, BD completed the sale of the Clontech unit of the BD Biosciences segment. Results reported as Discontinued Operations.
2005-06-30divestiture_reductionannounced2005-07-012005-12-31GlobalBD Biosciences (Clontech)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement signed July 1, 2005 to sell Clontech for approximately $60 million; expected to close in Q4 2005 subject to regulatory approvals. No employee counts disclosed.
2004-09-30restructuringin_progress53320022004-12-31China, France, Germany, Ireland, Mexico, United StatesBD Medical — manufacturing restructuring programUSD 26 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cumulative program scope announced in fiscal 2002 (~$26 million of charges recorded in fiscal 2002; none in fiscal 2004). As of September 30, 2004 one employee remains to be severed, with the remaining termination and accrued severance payment expected in the first quarter of fiscal 2005 (quarter ending December 31, 2004). Fiscal 2004 activity: $1.0 million of severance payments, leaving a $0.2 million severance accrual at year-end.
2004-09-30divestiture_reductionannounced2004-09-28United States (Palo Alto, CA and Mountain View, CA) and JapanBD Biosciences — Clontech unitUSD 124 (millions)discontinued_operations_footnote
f5-10k / GLM-5.3-flash-HTML		Board approved a plan to sell the Clontech unit; a pre-tax charge of approximately $124 million ($115 million after tax) was recorded to write down Clontech net assets to estimated fair value. Employee count of the divested unit is not disclosed; Clontech results are reported as discontinued operations and its assets ($63.7 million) and liabilities ($14.2 million) are classified as held for sale at fiscal year-end.
2004-09-30acquisition_additioncompleted2004-07-01BD Biosciences — Immunocytometry Systems unitUSD 1 (millions)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		On July 1, 2004, BD acquired all outstanding equity of Atto Bioscience, Inc., a privately held company specializing in optical instrumentation and reagents for live-cell analysis, for approximately $25.8 million in cash. Number of employees acquired is not disclosed. Charge shown is for purchased in-process research and development.
2004-09-30restructuringin_progress5332004-12-31China, France, Germany, Ireland, Mexico, United StatesBD MedicalUSD 22 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end: 533 terminations under the fiscal 2002 Medical manufacturing restructuring program; only one employee remained to be severed at 2004-09-30, with accrual payments of $1.0 million and adjustments of $0.6 million in fiscal 2004. Charge shown is the full fiscal 2002 program charge, not a fiscal 2004 charge.
2004-09-30acquisition_additioncompleted2004-07-012004-07-01United StatesBD Biosciences — Immunocytometry Systemsbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Atto Bioscience, Inc. for approximately $25.8 million cash; acquired headcount not disclosed. A $1.1 million in-process R&D charge was recorded.
2004-09-30divestiture_reductionannounced2004-09-28United States, JapanBD Biosciences — ClontechUSD 124 (millions)discontinued_operations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Board approved plan to sell the Clontech unit; charge is a pre-tax write-down of net assets to fair value, not severance. Associated headcount not disclosed; four leased Clontech facilities (approx. 157,000 sq ft) reclassified as held for sale.
2004-09-30restructuringcompleted5332002-01-012005-03-31China, France, Germany, Ireland, Mexico, United StatesBD MedicalUSD 26 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Manufacturing restructuring program initiated in fiscal 2002. As of September 30, 2004, one employee remained to be severed, with completion expected in Q1 2005. Total charges in 2002 were $26 million for severance.
2004-09-30restructuringcompleted5332002-06-302005-03-31China, France, Germany, Ireland, Mexico, and the United StatesBD MedicalUSD 22 ()restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Manufacturing restructuring program in BD Medical segment initiated in fiscal 2002. Total employees affected: 533. As of Sept 30, 2004, one employee remains to be severed, expected to complete in Q1 2005. Charge of $21.5 million recorded in FY2002.
2004-06-30restructuringin_progress5332001-10-012004-12-31China, France, Germany, Ireland, Mexico, United StatesBD MedicalUSD 22 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Fiscal 2002 program; 525 of 533 targeted employees severed as of 2004-06-30. Remaining terminations expected substantially complete in Q1 FY2005. Charge of $21,508 thousand recorded in fiscal 2002.
2004-06-30acquisition_additionannounced2004-07-012004-07-01BD BiosciencesUSD 25 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Atto Bioscience, Inc. for approximately $25.3 million in cash; purchase price disclosed but no headcount figure provided. To be recorded in Q4 FY2004.
2004-06-30restructuringin_progress5332002-01-012005-03-31China, France, Germany, Ireland, Mexico, United StatesMedicalUSD 22 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2002 manufacturing restructuring program. 525 of 533 targeted employees severed as of June 30, 2004. Remaining terminations expected to be substantially completed in Q1 FY2005. Accrued severance balance of $800 thousand as of June 30, 2004.
2004-03-31restructuringin_progress5332004-06China, France, Germany, Ireland, Mexico, United StatesBD Medical (manufacturing)USD 22 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Program announced in fiscal 2002; 524 of 533 targeted employees severed as of 2004-03-31. Charge recorded in fiscal 2002; remaining terminations and severance payments expected substantially complete by June 2004. Severance accrual balance at 2004-03-31 was $0.8 million with $1.0 million paid during the six months then ended.
2004-03-31restructuringin_progress5332002-01-012004-06-30China, France, Germany, Ireland, Mexico, United StatesMedicalUSD 22 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		2002 manufacturing restructuring program aimed at optimizing efficiencies. 524 of 533 targeted employees severed as of March 31, 2004. Remaining terminations expected to be completed by June 2004.
2003-12-31restructuringin_progress53320022004-06-30China, France, Germany, Ireland, Mexico, United StatesBD Medical — manufacturingUSD 22 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		521 of 533 targeted employees severed as of 2003-12-31; remaining severance expected substantially paid by June 2004. Charge recorded in fiscal year 2002.
2003-12-31restructuringin_progress5332002-10-012004-06-30China, France, Germany, Ireland, Mexico, United StatesMedicalUSD 22 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2002 manufacturing restructuring program. 521 of 533 targeted employees severed as of Dec 31, 2003. Remaining accrual balance $800k severance, $100k restructuring.
2003-09-30restructuringin_progress53320022004-06China, France, Germany, Ireland, Mexico, and the United StatesBD Medical — manufacturingUSD 18,533 (thousands)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Multi-year program: charges of $9,937 and $15,760 (thousands) recorded in Q2 and Q3 of fiscal 2002, including total exit costs of $19,171 of which $18,533 was severance; MD&A cites roughly $26 million of program charges plus $7 million of related manufacturing costs. During fiscal 2003, $11,600 of severance was paid, leaving a $1,800 severance accrual at September 30, 2003; 15 employees remained to be severed, with accrued severance expected to be substantially paid by June 2004. Headcount figure is the total program level, not fiscal-2003-only terminations.
2003-09-30restructuringin_progress5332001-10-012004-06-30China, France, Germany, Ireland, Mexico, United StatesBD MedicalUSD 22 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end: program announced in FY2002; 15 employees remained to be severed at 2003-09-30, with terminations and severance payments expected complete by June 2004. Charge shown is total FY2002 special charges of $21.5M, not a FY2003 charge; no special charges were recorded in FY2003
2003-09-30restructuringcompleted5332002-07-012004-06-30China, France, Germany, Ireland, Mexico, United StatesBD MedicalUSD 25,697 (thousands)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Manufacturing restructuring program in BD Medical segment initiated in FY2002. 533 employees terminated. As of Sept 30, 2003, 15 employees remain to be severed. Remaining terminations expected to be completed and severance paid by June 2004. Total special charges recorded in FY2002 were $25.7 million ($9.9M Q2 + $15.8M Q3), net of $4.2M reversals.
2003-09-30restructuringin_progress5332002-09-302004-06-30China, France, Germany, Ireland, Mexico, and the United StatesBD MedicalUSD 22 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Fiscal 2002 manufacturing restructuring program. 15 employees remained to be severed as of Sept 30, 2003. Related accrued severance expected to be substantially paid by June 2004.
2003-06-30restructuringin_progress5332003-09-30China, France, Germany, Ireland, Mexico, United StatesBD Medical Systems — manufacturingUSD 16 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Manufacturing restructuring program; 490 of 533 targeted employees severed as of 2003-06-30. Charge recorded in Q3 FY2002; Q2 FY2002 charge was $9.937M. Severance accrual balance at 2003-06-30 was $3.2M.
2003-06-30restructuringin_progress6002004-03-31WorldwideAll businesses, functional areas, and regionsUSD 58 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Worldwide organizational restructuring to align infrastructure with growth programs; 15 of 600 targeted employees remained to be severed as of 2003-06-30. Completion delayed approximately six months due to facility transition delays. Severance accrual balance at 2003-06-30 was $0.6M.
2003-06-30plant_closurein_progress2002003-09-30United States — Hancock, New YorkSurgical blade manufacturingUSD 91 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Surgical blade plant closure; production ceased September 2002. Of 200 planned terminations, 50 terminated Sept 1999 and 122 terminated Sept 2002; remaining terminations substantially completed as of 2003-06-30 with accruals expected to be paid over the next three months.
2003-06-30restructuringin_progress5332002-01-012003-09-30China, France, Germany, Ireland, Mexico, United StatesMedicalUSD 25,697 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2002 manufacturing restructuring. 490 of 533 targeted employees severed as of June 30, 2003. Remaining terminations expected by end of fiscal 2003. Original charges were $9,937 (Q2 FY02) and $15,760 (Q3 FY02), partly offset by $4,189 reversals.
2003-06-30restructuringin_progress6002000-01-012004-03-31WorldwideAll businessesUSD 57,514 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2000 organizational restructuring. 15 of 600 targeted employees remained to be severed as of June 30, 2003. Completion delayed to March 2004 due to facility transition delays.
2003-06-30plant_closurecompleted2001998-01-012003-09-30Hancock, New YorkMedicalUSD 90,945 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 1998 restructuring including closure of surgical blade plant. 50 terminated in Sept 1999, 122 in Sept 2002. Remaining terminations substantially completed as of June 30, 2003.
2003-03-31restructuringin_progress5332002-04-012003-09-30China, France, Germany, Ireland, Mexico, United StatesBD Medical Systems (manufacturing)USD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Manufacturing restructuring program; 414 of 533 targeted employees severed as of 2003-03-31. Charge of $9,937 thousand recorded in Q2 FY2002. Remaining terminations expected complete by end of fiscal 2003.
2003-03-31restructuringin_progress6002000-01-012004-03-31WorldwideAll businesses, functional areas and regionsUSD 58 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Worldwide organizational restructuring for cost reduction; 15 of 600 targeted employees remained to be severed as of 2003-03-31. Completion delayed approximately six months due to facility transition delays.
2003-03-31plant_closurein_progress2001998-01-01Hancock, New York, United StatesSurgical blade manufacturingUSD 91 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Surgical blade plant closure; production ceased September 2002. Of 200 planned terminations, 7 employees remained as of 2003-03-31. Remaining accruals to be paid upon conclusion of shutdown activities.
2003-03-31restructuringin_progress5332002-01-012003-09-30China, France, Germany, Ireland, Mexico, United StatesMedicalUSD 25,697 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Manufacturing restructuring program. 414 employees severed as of March 31, 2003. Remaining terminations expected to be completed by end of fiscal 2003. Total charges recorded in FY2002 were $9,937 (Q2) and $15,760 (Q3), net of $4,189 reversals.
2003-03-31restructuringin_progress6002000-01-012004-03-31WorldwideAll businessesUSD 57,514 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Worldwide organizational restructuring plan for cost reduction. 15 employees remained to be severed as of March 31, 2003. Completion delayed to March 2004 due to facility transition delays.
2003-03-31plant_closurein_progress2001998-01-012003-09-30Hancock, New YorkManufacturingUSD 90,945 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of surgical blade plant. Production ceased September 2002. 193 employees terminated previously; 21 terminated in first six months of FY2003. Seven employees remained to be terminated as of end of Q2.
2002-12-31restructuringin_progress5332003-09-30China, France, Germany, Ireland, Mexico, United StatesBD Medical Systemsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Manufacturing restructuring initiated in fiscal 2002; 384 of 533 targeted employees severed as of 2002-12-31. Severance accrual balance $12,400 thousand and restructuring accrual $500 thousand at quarter-end. Program presented as a consolidated total, not split by geography. Exact announcement date not disclosed.
2002-12-31restructuringin_progress6002003-09-30WorldwideAll businesses, functional areas and regionsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Worldwide organizational restructuring plan originally targeting 600 employee terminations; 15 remained to be severed as of 2002-12-31. Severance accrual $600 thousand and other accrual $700 thousand at quarter-end. Count shown is the original program target, not current-period activity. Exact announcement date not disclosed.
2002-12-31plant_closurein_progress11Hancock, New York, United StatesSurgical blade manufacturingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Production at the Hancock surgical blade plant ceased in September 2002; 11 employees remained to be terminated at quarter-end, with a related severance accrual of $1,900 thousand payable upon conclusion of remaining shutdown activities. Count reflects remaining separations, not the full program. Exact announcement date not disclosed.
2002-12-31restructuringin_progress5332002-09-302003-09-30China, France, Germany, Ireland, Mexico, United StatesMedicalUSD 21,508 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Manufacturing restructuring program initiated in FY2002. 384 of 533 targeted employees severed as of Dec 31, 2002. Accrued severance balance $12.4M.
2002-12-31restructuringin_progress6002000-09-302003-09-30WorldwideAll businessesUSD 57,514 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		FY2000 organizational restructuring. 15 of 600 targeted employees remained to be severed as of Dec 31, 2002. Accrued severance balance $0.6M.
2002-12-31plant_closurein_progress1998-09-302003-09-30Hancock, New YorkMedicalUSD 90,945 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		FY1998 restructuring including closure of surgical blade plant. Production ceased Sept 2002. 11 employees remained to be terminated as of Dec 31, 2002. Accrued severance balance $1.9M.
2002-09-30restructuringin_progress5332003-09-30China, France, Germany, Ireland, Mexico, United StatesBD Medical Systems — manufacturingUSD 26 (millions)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Manufacturing restructuring program aimed at optimizing manufacturing efficiencies. Special charges of $9,937K in Q2 and $15,760K in Q3 FY2002, including $18,533K severance and $6,526K asset write-downs (of which $5,109K China machinery impairment). 268 of the 533 targeted employees had been severed as of 2002-09-30, with $5,100K severance paid and $13,400K accrued. MD&A additionally cites roughly $7M of related accelerated depreciation in cost of products sold. Specific announcement date not disclosed; terminations expected complete and severance substantially paid by end of FY2003.
2002-09-30restructuringin_progress6002000-092003-06-30Worldwide (FY2002 reversal activity primarily Europe)All businesses, functional areas and regionsUSD 4,189 (thousands)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cumulative-to-date for multi-year program approved September 2000 (prior fiscal years): $33,000K exit costs originally recorded, of which $31,700K severance, for 600 targeted terminations; approximately 15 employees remained to be severed at 2002-09-30. FY2002 activity was a $4,189K reversal of prior charges (primarily severance and lease cancellation costs) recorded in Q3 FY2002 following a modified European restructuring plan approved that quarter. Remaining terminations and severance payments expected substantially complete by first half of 2003.
2002-09-30plant_closurein_progress20019982002-12Hancock, New York, United StatesMedical segment — surgical blade plantUSD 9,900 (thousands)restructuring_footnote
f5-10k / GLM-5.3-flash-HTML		Cumulative-to-date for multi-year closure initiated in fiscal 1998 (delayed from original May 2000 target): an estimated 200 employee terminations, with a $9,900K severance charge plus $2,400K other employee termination costs. Production ceased in September 2002; approximately 28 employees remained to be terminated at fiscal year-end. Accruals expected to be substantially paid by December 2002.
2002-09-30restructuringin_progress5332003-09-30China, France, Germany, Ireland, Mexico, United StatesBD Medical Systems — manufacturingUSD 19 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Manufacturing restructuring program; 268 of 533 targeted employees severed as of 2002-09-30. Severance accrual $13.4M remaining at year-end. Total FY2002 special charges for program were $25.7M including $6.5M asset write-downs (China impairments $5.1M).
2002-09-30plant_closurein_progress282002-12-31Hancock, New York, United StatesBD Medical Systems — surgical blade manufacturingrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Production at Hancock facility ceased September 2002; approximately 28 employees remain to be terminated upon completion of shutdown activities. Part of 1998 restructuring plan; accruals expected substantially paid by December 2002. Original 1998 plan targeted ~200 employees.
2002-09-30restructuringin_progress152003-03-31WorldwideCorporate / all segmentsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Worldwide organizational restructuring plan approved September 2000; approximately 15 of original 600 targeted employees remained to be severed at 2002-09-30, expected completed by first half of 2003. FY2002 activity only: $4.2M reversal of prior-year charges and $2.6M severance payments.
2002-09-30restructuringin_progress5332002-09-302003-09-30China, France, Germany, Ireland, Mexico, United StatesMedical SystemsUSD 26 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Manufacturing restructuring program in BD Medical Systems segment. 268 employees severed as of Sept 30, 2002. Expected completion by end of fiscal 2003. Charge includes $18.5M severance and $6.5M asset write-downs. Net special charges were $21.5M after $4.2M reversal of prior year charges.
2002-09-30restructuringin_progress5332002-09-302003-09-30China, France, Germany, Ireland, Mexico, and the United StatesBD Medical SystemsUSD 18,533 (thousands)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Manufacturing restructuring program aimed at optimizing manufacturing efficiencies. 268 of 533 targeted employees severed as of Sept 30, 2002. Severance accrual balance $13,400 thousand.
2002-06-30restructuringin_progress5332003-09-30China, France, Germany, Ireland, Mexico, United StatesBD Medical Systems (manufacturing)USD 26 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Gross FY2002 charges of $25.7M: $19.2M exit costs (incl. $18.5M severance) plus $6.5M asset write-downs; 74 employees severed as of 2002-06-30. Net nine-month special charge $21.5M after $4.2M reversal of FY2000 charges. Program began in Q2 FY2002; no announcement date stated.
2002-06-30restructuringin_progress3020002002-12-31WorldwideAll businesses, functional areas and regionsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Worldwide organizational restructuring; 600 employees originally targeted, approximately 30 remained to be severed at 2002-06-30. $4.2M of FY2000 charges reversed in Q3 FY2002 (severance and lease cancellation).
2002-06-30plant_closurein_progress15019982002-12-31United States (Hancock, New York)Surgical blade manufacturingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closure of Hancock surgical blade plant; remaining 150 employees to be terminated upon closure, which has been delayed. Original FY1998 special charge $90.9M; accrual balance at 2002-06-30 was $8.2M.
2002-06-30divestiture_reductionannounced2002-04-08Critical care product lineMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Non-binding letter of intent with AorTech International plc to sell critical care product line; contingent on definitive agreement and AorTech approvals. Estimated non-cash pre-tax loss of $35-40M if completed; no headcount impact disclosed.
2002-06-30restructuringin_progress5332002-01-012003-09-30China, France, Germany, Ireland, Mexico, and the United StatesMedicalUSD 18,533 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Manufacturing restructuring program aimed at optimizing efficiencies. 74 employees severed as of June 30, 2002. Completion expected by end of fiscal 2003.
2002-06-30restructuringin_progress302000-01-012002-12-31WorldwideAll businessesUSD 1,500 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Remainder of fiscal year 2000 worldwide organizational restructuring plan. 30 employees remained to be severed as of June 30, 2002.
2002-06-30plant_closurein_progress1501998-01-012002-12-31Hancock, New YorkMedicalUSD 6,400 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of surgical blade plant. 150 employees to be terminated upon closure. Completion expected by December 2002.
2002-03-31restructuringin_progress2672002-12-31France, Mexico, China, and FloridaBD Medical Systems (manufacturing)USD 4,828 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Severance portion of $9,937 thousand Q2 FY2002 special charge; remainder ($5,109 thousand) was an asset write-down in China. Terminations expected substantially paid by Q1 FY2003.
2002-03-31restructuringannouncedEuropeBD Medical Systems (manufacturing)USD 12 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Additional special charges anticipated in Q3 FY2002 under the same manufacturing restructuring program, primarily severance in Europe; estimated four cents per share.
2002-03-31restructuringin_progress54220002002-09-30WorldwideAll businesses, functional areas and regionsUSD 57,514 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		542 of a targeted 600 employees severed as of 2002-03-31; remaining terminations and accrued severance expected substantially completed and paid no later than second half of fiscal 2002. Charge is the original fiscal 2000 total.
2002-03-31plant_closurein_progress15019982002-12-31Hancock, New York, United StatesSurgical blade manufacturingUSD 90,945 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closure of surgical blade plant; production line relocation delayed. Remaining 150 employees to be terminated upon plant closure; accruals expected substantially paid by December 2002. Charge is the original fiscal 1998 total.
2002-03-31restructuringin_progress2672002-03-312003-03-31France, Mexico, China, and FloridaMedicalUSD 4,828 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Part of manufacturing restructuring program; terminations expected to be completed and accrued severance substantially paid by Q1 FY2003.
2002-03-31restructuringin_progress2002-03-31ChinaMedicalUSD 5,109 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Write-down to net realizable value of impaired assets; depreciation accelerated over remaining exit plan period.
2002-03-31restructuringin_progress582000-01-012002-09-30GlobalAll businessesrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		FY2000 plan: 600 targeted, 542 severed as of March 31, 2002. Remaining 58 terminations expected substantially completed by H2 FY2002.
2002-03-31plant_closurein_progress1501998-01-012002-12-31Hancock, New YorkMedicalrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		FY1998 plan: Surgical blade plant closure. Remaining 150 employees to be terminated upon closure; accruals expected substantially paid by Dec 2002.
2001-12-31restructuringin_progress6002002-09-30WorldwideAll businesses, functional areas and regionsUSD 58 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Worldwide organizational restructuring plan targeting elimination of approximately 600 positions; 542 of the 600 had been severed as of 2001-12-31. Remaining terminations and accrued severance expected substantially completed and paid no later than the second half of fiscal 2002. Special charge of $57,514 thousand was recorded in fiscal 2000 (prior to this reporting period); severance accrual balance was $5,100 thousand at 2001-12-31. Announcement date not disclosed in this filing.
2001-12-31plant_closurein_progress1502002-12United States (Hancock, New York)Manufacturing — surgical blade plantUSD 91 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		1998 restructuring plan includes closing the Hancock, NY surgical blade plant; move of a production line has been delayed. The remaining 150 employees will be terminated upon closure; plan now expected completed and accruals substantially paid by December 2002. Special charge of $90,945 thousand was recorded in fiscal 1998 (prior to this reporting period); accrual balance at 2001-12-31 was $9,300 thousand across severance, restructuring and other. Total program headcount affected not disclosed; only the remaining 150 is quantified. Announcement date not disclosed in this filing.
2001-12-31restructuringannounced2001-01Not specifiedMedical Systems — manufacturing facilitiesMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Relatively small-scale restructuring of manufacturing facilities in the Medical segment; special charges of approximately $25 to $28 million, relating primarily to severance costs, planned for recording in the second quarter of fiscal 2002. Employees affected not disclosed. Filing states the restructuring commenced in 'January 2001'; given the planned fiscal 2002 second-quarter charge, this appears to be a typographical error for January 2002.
2001-12-31restructuringin_progress582000-10-012002-06-30WorldwideAll businesses, functional areas and regionsUSD 16 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2000 plan targeted 600 employees; 542 severed as of Dec 31, 2001. Remaining 58 terminations expected by H2 FY2002. Accrual balance $16.3M.
2001-12-31plant_closurein_progress1501998-10-012002-12-31Hancock, New YorkMedicalUSD 9 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 1998 plan to close surgical blade plant. 150 employees to be terminated upon closure. Accrual balance $9.3M.
2001-12-31restructuringannounced2001-01-01United StatesMedicalUSD 27 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Small-scale restructuring of manufacturing facilities commenced Jan 2001. Charges of $25-28M expected in Q2 FY2002.
2001-09-30restructuringin_progress5402000-092002-06-30WorldwideAll segmentsUSD 33 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cumulative through fiscal year-end: 540 of 600 targeted employees severed as of 2001-09-30; $33M severance charge recorded in FY2000 (prior year); FY2001 activity comprised $25.4M in severance payments from accrual; remaining terminations expected by Q2 FY2002
2001-09-30plant_closurein_progress15019982002-12-31Hancock, New York, United StatesMedical Systemsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		1998 restructuring plan for surgical blade plant closure; 150 remaining employees to be terminated upon closure; original $15.4M severance charge recorded in FY1998; completion expected by December 2002; closure delayed due to blade technology issues and safety-device reprioritization
2001-09-30divestiture_reductioncompletedTransdermal business unitMD&A
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Divested in first quarter of fiscal 2001; headcount not disclosed
2001-09-30acquisition_additioncompleted2001-012001-01Biosciencesbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Gentest Corporation acquired January 2001 for approximately $29M cash; headcount not disclosed
2001-09-30restructuringin_progress6002000-092002-06-30WorldwideAll businesses, functional areas and regionsUSD 33 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Worldwide organizational restructuring approved in September 2000. Plan provides for termination of approximately 600 employees. As of September 30, 2001, approximately 540 had been severed. Remaining terminations expected to be substantially completed and paid no later than the second quarter of 2002. Includes $32 million severance costs and $6 million impaired assets/exit costs recorded in 2000.
2001-09-30voluntary_separationcompleted1331999-072000-09-30Selected locationsVariousUSD 18 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Enhanced voluntary retirement incentive program offered in fiscal 1999 to 176 eligible employees. 133 participants accepted. Program completed within one year.
2001-09-30restructuringcompleted611999-072000-09-30VariousMedical Systems (Home Healthcare)USD 3 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Exit of certain product lines primarily in home healthcare area in fiscal 1999. Involved termination of 61 employees. Completed and substantially all accrued liabilities paid within one year.
2001-09-30plant_closurein_progress20019982002-12-31Hancock, New YorkMedical Systems (Surgical Blades)USD 15 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Closure of surgical blade plant in Hancock, NY initiated in 1998. Original plan to terminate ~200 employees by May 2000 delayed due to technology issues and market demand. Revised completion expected by December 2002. 50 employees terminated in Sept 1999; remaining 150 to be terminated upon closure.
2001-09-30restructuringcompleted18019981999-09-30Brazil, Spain, Australia, FranceManufacturingUSD 23 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Consolidation of production functions in Brazil, Spain, Australia, and France initiated in 1998. Approximately 150 employees affected by consolidations (Australia/France completed with ~30 terminations; Brazil/Spain activities reversed/not exited). Additional 30 employees terminated in Australia/France.
2001-09-30restructuringin_progress6002000-092002-06-30WorldwideAll businesses, functional areas and regionsUSD 33 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Worldwide organizational restructuring approved in September 2000. Plan provides for termination of approximately 600 employees. As of Sept 30, 2001, 540 severed. Remaining expected to be completed no later than Q2 2002. Charge includes $32M severance and $6M impaired assets/exit costs.
2001-09-30plant_closurein_progress20019982002-12-31Hancock, New YorkMedical Systemsrestructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Closure of surgical blade plant initiated in 1998. Delayed due to technology issues and demand surge. Expected completion and substantial payment of accruals by December 2002. 150 employees remaining to be terminated upon closure.
2001-06-30restructuringin_progress6002000-092001-09-30WorldwideAll businesses, functional areas and regionsUSD 33 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved September 2000 for cost reduction; $31.7M of the $33M charge was severance. Approximately 520 of the 600 targeted positions had been severed as of 2001-06-30; remaining terminations and accrued severance expected substantially completed and paid by end of fiscal 2001. Also includes $4.5M asset impairments and $20M latex litigation defense accrual, not workforce-related.
2001-06-30plant_closurein_progress15019982002-12-31United States (Hancock, New York)Medical segment — surgical blade manufacturingUSD 10 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Surgical blade plant closure with production transfer to Puerto Rico; 50 employees terminated in September 1999, remaining 150 to be terminated upon closure. Closure date slipped from May 2000 to latter part of fiscal 2001 and now expected substantially complete by December 2002 due to blade technology issues, demand surge, and re-prioritization for safety-engineered devices. An additional $2.4M other employee termination charge was recorded with the original severance charge; severance estimates increased with the extension, offset by other savings.
2001-06-30restructuringin_progress6002000-09-012001-09-30WorldwideAll businesses, functional areas and regionsUSD 33,000 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2000 worldwide organizational restructuring plan. 520 of 600 targeted employees severed as of June 30, 2001. Remaining terminations expected to be substantially completed and paid by end of fiscal 2001.
2001-06-30plant_closurein_progress2001998-06-012002-12-31Hancock, New YorkMedicalUSD 12,300 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Closure of surgical blade plant. Originally estimated 200 employees terminated. 50 terminated in Sept 1999. Remaining 150 to be terminated upon closure. Completion revised to Dec 2002 due to technology issues and demand surge.
2001-06-30restructuringin_progress1501998-01-012001-09-30Brazil, Spain, Australia, FranceManufacturingUSD 3,100 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Consolidation of production functions. Approx 150 employees estimated affected. Australia and France activities completed with approx 30 employees terminated. Brazil and Spain activities reversed/not exited as planned.
2001-06-30voluntary_separationcompleted1331999-07-012000-09-30Selected locationsVariousUSD 4,400 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Voluntary retirement program offered to 176 employees in FY1999. 133 participants accepted. Program completed within one year.
2001-06-30restructuringcompleted611999-07-012000-09-30Medical SegmentHome HealthcareUSD 2,700 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Exit of certain product lines in Medical segment (home healthcare). Involved termination of 61 employees. Completed and substantially all accrued liabilities paid within one year.
2001-03-31restructuringin_progress6002000-09-012001-09-30WorldwideAll businesses, functional areas and regionsUSD 33 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved September 2000; approximately 470 of 600 targeted employees severed as of March 31, 2001. Remaining terminations expected substantially completed and paid by end of fiscal 2001.
2001-03-31plant_closurein_progress1501998-06-012002-12-31Hancock, New York, United StatesMedical segment — surgical blade manufacturingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closure date revised to latter part of fiscal 2001; remaining 150 employees to be terminated upon closure. Plan expected substantially paid by December 2002. Severance estimates increased due to extension.
2001-03-31acquisition_additioncompleted2001-01-102001-01-10United StatesBiosciences segmentUSD 29 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Gentest Corporation completed January 10, 2001 for approximately $29 million cash. Headcount added not disclosed.
2001-03-31restructuringin_progress6002000-09-012001-09-30WorldwideAll businesses, functional areas and regionsUSD 33,000 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 2000 plan. 470 severed as of March 31, 2001. Remaining expected to be completed by end of fiscal 2001.
2001-03-31plant_closurein_progress2001998-06-012002-12-31Hancock, New YorkMedicalUSD 12,300 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 1998 plan. Closure delayed. 50 terminated previously. Remaining 150 to be terminated upon closure.
2001-03-31restructuringin_progress1501998-01-01Brazil, Spain, Australia, FranceManufacturingUSD 3,100 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 1998 consolidation plan. Australia and France completed (30 employees). Brazil and Spain activities not exited as planned.
2001-03-31voluntary_separationcompleted1331999-07-012000-09-30Selected locationsUSD 17,900 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 1999 voluntary retirement program. 176 eligible, 133 accepted. Completed within one year.
2001-03-31restructuringcompleted611999-07-012000-09-30MedicalUSD 2,700 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Fiscal 1999 exit of home healthcare product lines. Completed within one year.
2000-12-31restructuringin_progress6002000-092001-09-30WorldwideCompany-widerestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Targeted 600 employees for severance under a worldwide organizational restructuring; more than two-thirds severed as of 2000-12-31, remainder expected by end of fiscal 2001. Charge recorded in September 2000 (prior quarter). Severance accrual payments of $10.8M during the quarter across all special charge programs.
2000-12-31plant_closurein_progress15019992002-03-31United StatesManufacturing — surgical blade plantrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Part of FY1999/FY1998 restructuring programs. Approximately 100 positions already eliminated as of 2000-12-31; an additional 150 people expected to be affected by planned closure of a U.S. surgical blade plant scheduled for first half of fiscal 2002. Remaining accruals consist primarily of severance.
2000-12-31restructuringin_progress6002000-09-302001-09-30WorldwideUSD 29,200 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Worldwide organizational restructuring initiated in Sept 2000. As of Dec 31, 2000, more than two-thirds of targeted 600 employees severed. Remaining terminations expected by end of fiscal 2001. Severance accrual balance $29.2M.
2000-12-31restructuringin_progress2502002-03-31United StatesManufacturingUSD 2,750 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Related to planned closure of surgical blade plant. Approx 100 positions eliminated as of Dec 31, 2000; additional 150 affected expected. Closure scheduled for first half of fiscal 2002. Restructuring accrual balance $2.75M.
2000-09-30restructuringin_progress6002001-09-30WorldwideVarious functions worldwideUSD 31,700 (thousands)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Severance charge of $31.7M for termination of approximately 600 employees; majority expected within first half of FY2001, remainder by end of FY2001. Total special charges for the program were $57.5M including $5.8M impaired assets/exit costs and $4.5M asset write-downs.
2000-09-30plant_closureannounced1502002-03-31United StatesSurgical blade manufacturingrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program originating in FY1998; closure of a U.S. surgical blade plant scheduled for first half of FY2002. Approximately 100 employees already terminated as of Sept 30, 2000; an additional 150 expected to be affected. Remaining accruals for severance included in the $40.0M total severance accrual balance.
2000-09-30restructuringin_progress6002000-09-302001-09-30WorldwideVarious functionsUSD 38 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Worldwide organizational restructuring resulting in termination of approximately 600 employees. Charges included $32 million for severance and $6 million for impaired assets/exit costs. Majority of terminations expected in first half of coming year, remainder by end of fiscal 2001.
2000-09-30voluntary_separationcompleted1331999-01-011999-09-30Selected locationsVariousUSD 18 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Enhanced retirement incentive program offered to 176 employees; accepted by 133 participants. Recorded in fiscal 1999, disclosed in current filing for context.
2000-06-30plant_closurein_progress1002002-03-31United StatesManufacturing — surgical blade plantrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		1998 restructuring plan; about 100 positions eliminated as of 2000-06-30. An additional 150 people expected to be affected upon closure of a U.S. surgical blade plant scheduled for the first half of fiscal 2002; remaining accruals are primarily severance. Severance accrual balance was $8,900 thousand at 2000-06-30 (payments of $4,200 thousand during the nine months). Announcement date not disclosed in this filing.
2000-06-30restructuringin_progressrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring accrual roll-forward at 2000-06-30: severance $8,900, restructuring $3,350, other $2,600 (thousands); no employee counts disclosed for the restructuring and other components. Prior-year special charges of $76 million (exited product lines, asset impairment, enhanced voluntary retirement incentive program) relate to fiscal 1999, not this quarter.
2000-06-30restructuringin_progress1002002-03-31United StatesManufacturingUSD 9 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1998 restructuring plan; 100 positions eliminated as of June 30, 2000. Additional 150 people expected to be affected upon closure of U.S. surgical blade plant scheduled for first half of fiscal 2002. Remaining accruals relate primarily to severance.
2000-06-30restructuringin_progress2000-09-30USD 2 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Reserves related to Difco Laboratories acquisition (1997). Approximately $2,000 (thousands) of severance and exit cost reserves remained as of June 30, 2000. Company does not expect significant reserve balance to remain at year-end.
2000-03-31plant_closureannounced1502002-06-30United StatesManufacturing — surgical blade plantrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Part of the 1998 restructuring plan; closure of a U.S. surgical blade plant scheduled for the first half of fiscal year 2002. Remaining accruals consist primarily of severance. Approximately 100 positions had already been eliminated under this plan as of March 31, 2000.
2000-03-31restructuringin_progress100United StatesManufacturingrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated under the 1998 restructuring plan as of March 31, 2000; not specific to the current quarter. Severance accrual balance at March 31, 2000 was $9.6 million.
2000-03-31restructuringin_progress1002001-09-30United StatesManufacturingUSD 9,600 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1998 restructuring plan; 100 positions eliminated as of March 31, 2000. Accrual balance of $9,600 thousand relates primarily to severance.
2000-03-31plant_closureannounced1502001-09-30United StatesManufacturingrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1998 restructuring plan; closure of U.S. surgical blade plant scheduled for first half of fiscal 2002. 150 additional people expected to be affected.
2000-03-31restructuringin_progress2000-06-30USD 4,250 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1999 restructuring program; accrual balance of $4,250 thousand as of March 31, 2000.
2000-03-31restructuringin_progressUSD 4,400 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		1999 restructuring program; 'Other' accrual balance of $4,400 thousand as of March 31, 2000.
2000-03-31restructuringin_progress2000-06-30USD 3,700 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Difco Laboratories acquisition (1997); remaining reserves of $3,700 thousand for severance and exit costs. Expected to be substantially utilized over the next three months.
1999-12-31restructuringin_progress951998Not specifiedManufacturing operationsrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Cumulative positions eliminated under the 1998 restructuring plan as of 1999-12-31; plan included restructuring of certain manufacturing operations. Severance accrual balance at 1999-12-31 was $12,500 thousand.
1999-12-31plant_closureannounced15019982002-03-31United StatesManufacturing — surgical blade plantrestructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Remaining employees affected under the 1998 restructuring plan, related to planned closure of a U.S. surgical blade plant scheduled for the first half of fiscal year 2002 (fiscal year ends September 30). Remaining accruals consist primarily of severance.
1999-12-31restructuringin_progress1502001-09-30United StatesManufacturingrestructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Remaining affected employees related to planned closure of a surgical blade plant, scheduled for the first half of fiscal year 2002.
1999-09-30voluntary_separationcompleted1331999-04-011999-09-30United StatesSelected locationsUSD 17,871 (thousands)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Enhanced voluntary retirement incentive program offered April 1999 to 176 employees meeting age and service requirements; responses due May 25, 1999; 133 participants accepted. Charge includes separation pay and enhanced pension/retirement benefits.
1999-09-30restructuringin_progress951997-10-012001-09-30United StatesManufacturing operationsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY1998 restructuring program; 95 positions eliminated through FY1999 year-end, with an additional 150 people expected to be affected. Includes closure of a U.S. surgical blade plant scheduled for latter part of fiscal 2001. Charge of approximately $35,000 thousand recorded in FY1998 (prior year, not extracted).
1999-09-30restructuringcompleted1999-06-011999-09-30United StatesBD Medical Systems — home health care product linesUSD 75,553 (thousands)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Third quarter FY1999 special charges for exiting product lines (primarily home health care), asset impairment, and voluntary retirement program. Exit plans completed by year-end. Includes $46,125 thousand intangible write-off and other exit costs; excludes $26,868 thousand inventory write-off/returns reserve recorded in cost of products sold.
1999-09-30acquisition_additioncompleted1999-09-30GlobalMultiple segmentsUSD 381,530 (thousands)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Ten businesses acquired during fiscal 1999 for aggregate $381,530 thousand cash plus 357,522 shares of common stock. Headcount added not disclosed. Includes Clontech Laboratories ($201 million, August 1999), Biometric Imaging, Luther Medical Products, Critical Device Corporation, SAF-T-MED, Glentech, and others.
1999-09-30restructuringcompleted1999-07-011999-09-30GlobalMedical Systems, Biosciences, Preanalytical SolutionsUSD 76 (millions)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Third quarter 1999 special charges of $76 million associated with exiting product lines, impairment of assets, and enhanced voluntary retirement incentive program. Implementation of exit plans completed by year-end.
1999-09-30voluntary_separationcompleted1331999-04-011999-05-25Selected LocationsGlobalUSD 18 (millions)Notes to Consolidated Financial Statements - Note 5
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Enhanced retirement incentive program offered to 176 employees; 133 participants accepted. Charges include separation pay and enhanced pension/retirement benefits.
1999-09-30restructuringin_progress2451998-01-012001-09-30United StatesMedical SystemsUSD 35 (millions)Notes to Consolidated Financial Statements - Note 5
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		1998 restructuring plan included closure of surgical blade plant scheduled for FY2001. As of Sept 30, 1999, 95 positions eliminated, 150 additional expected to be affected.
1999-09-30voluntary_separationcompleted1331999-041999-05-25Selected locationsVariousUSD 17,871 (thousands)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Enhanced voluntary retirement incentive program offered in April 1999 to 176 employees; 133 participants accepted. Charges included special termination and severance benefits.
1999-09-30restructuringin_progress24519982001-09-30United StatesManufacturingUSD 35,000 (thousands)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		1998 restructuring plan included closure of surgical blade plant scheduled for late FY2001. As of Sept 30, 1999, 95 positions eliminated, additional 150 expected to be affected. Total 1998 charges approx $35M for severance/termination.
1999-06-30voluntary_separationcompleted1331999-04-011999-05-25Selected locations (United States)MultipleUSD 17,871 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Enhanced voluntary retirement incentive program offered April 1999 to 176 employees meeting age and service criteria; 133 accepted by May 25, 1999 deadline.
1999-06-30restructuringin_progress1999-04-012000-06-30GlobalHome healthcare self-monitoring and other exited product linesUSD 46,125 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Write-off of intangibles and other costs for exit of certain product lines and activities; no employee count disclosed. Implementation expected complete by latter part of fiscal 2000.
1999-06-30restructuringin_progress1999-04-012000-06-30GlobalProduct development ventures no longer pursuedUSD 17,857 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Write-down of investment assets related to discontinued product development ventures; no employee count disclosed.
1999-06-30acquisition_additioncompletedVariousMultipleUSD 153,247 (thousands)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Five businesses acquired during first nine months of fiscal 1999 for aggregate $153 million net of cash acquired; headcount added not disclosed.
1999-06-30acquisition_additionannounced1999-08-061999-09-30United States (California)Gene-based drug discovery and molecular biology researchUSD 200 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Revised agreement to acquire Clontech Laboratories, Inc. for $200 million cash; expected to close in Q4 fiscal 1999; headcount not disclosed.
1999-06-30voluntary_separationcompleted1331999-04-011999-06-30Selected locationsUSD 17,871 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Enhanced voluntary retirement incentive program offered in April 1999 to 176 employees; 133 accepted by May 25, 1999.
1999-06-30restructuringin_progress1999-04-012000-09-30Home healthcare self-monitoringUSD 46,125 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Exit of certain product lines and activities, primarily in home healthcare self-monitoring business. Implementation expected by latter part of fiscal year 2000.
1999-03-31voluntary_separationannounced1751999-041999-05-25United StatesSelected sites — salaried employeesMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Offered to 175 salaried employees meeting age and service criteria; participants must respond by May 25, 1999. Expenses to be recorded in Q3 upon acceptance. Enhanced pension, retirement benefits, and separation pay offered.
1999-03-31acquisition_additionannounced1999-04-271999-09-30United StatesGene-based drug discovery and molecular biology researchUSD 200 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock acquisition of Clontech Laboratories valued at approximately $200 million; expected to complete by end of Q3 FY1999. Headcount not disclosed. To be accounted for as pooling of interests.
1999-03-31voluntary_separationannounced1751999-04-011999-05-25Selected sitesSalaried employeesMD&A
f5-10q / Qwen3.6-27B-Q8_0		Enhanced retirement incentive offered to 175 salaried employees meeting age/service requirements; response due May 25, 1999. Expenses to be recorded in Q3 upon acceptance.
1998-09-30restructuringin_progress3501998-06-301999-12-31United StatesMedical Supplies and DevicesUSD 35 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Third quarter 1998 restructuring includes closure of a US surgical blade plant and consolidation of production functions; approximately 350 people affected; total special charges of $90.9M including $38M goodwill impairment and $18M other one-time charges; program substantially complete over next 12-18 months.
1998-09-30acquisition_additioncompletedVariousMedical Supplies and Devices / Diagnostic SystemsUSD 546 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Six businesses acquired during fiscal 1998 for aggregate $545.6M cash plus up to 595,520 shares; includes MDD acquisition for ~$457M. Headcount added through acquisitions not disclosed.
1998-09-30restructuringin_progress3501998-07-011999-09-30United StatesMedical Supplies and DevicesUSD 35 (thousands)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Closure of surgical blade plant and consolidation of production functions. Approximately 350 people affected. Charges of $35,000 related to severance and termination costs. Completion expected over 12-18 months.
1998-09-30restructuringin_progress3501998-07-011999-09-30United StatesManufacturingUSD 35 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Closure of surgical blade plant and consolidation of production functions. Approximately $35 million in special charges related to severance and termination costs. Plan to be substantially completed over next 12-18 months.
1998-06-30restructuringin_progress1998-05-211999-12-31Manufacturing and administrative activitiesUSD 90,945 (thousands)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Special charges recorded in Q3 FY1998 primarily for restructuring certain manufacturing operations and writing down impaired assets. Board-approved plan announced via Form 8-K dated May 21, 1998; implementation expected to be completed by the end of 1999. No number of employees affected disclosed. Note 4 also includes approximately $11,000 thousand of reengineering charges for an enterprise-wide business systems upgrade, reported largely in selling and administrative expense.
1998-06-30acquisition_additioncompleted1998-04-03Medical Supplies and DevicesUSD 30,000 (thousands)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of the Medical Devices Division of The BOC Group (Ohmeda) completed in April 1998 for approximately $452,000 thousand cash; consummation announced by Form 8-K dated April 3, 1998. Approximately $360,000 thousand of goodwill recorded. Charge shown is purchased in-process R&D; Q3 also included about $15,000 thousand of integration charges. Added roughly $40 million to Medical segment revenues in the quarter. No headcount acquired disclosed.
1998-06-30restructuringin_progress1998-05-211999-12-31Manufacturing and administrative activitiesUSD 90,945 (thousands)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Special charges of $90.9 million recorded in Q3 1998 primarily associated with restructuring of certain manufacturing operations and write-down of impaired assets. Implementation expected to be completed by end of 1999. Employee count not disclosed.
1998-06-30acquisition_additioncompleted1998-04-03Medical Devices Division (MDD)USD 452,000 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Medical Devices Division of The BOC Group completed in April 1998 for approx $452 million. Headcount added not disclosed.
1997-12-31acquisition_additioncompletedMedical Supplies and Devices (ophthalmic surgical and anesthesia products)USD 40 (millions)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of an ophthalmic surgical and anesthesia products manufacturer for $40 million; target annual revenues about $22 million. No headcount disclosed.
1997-12-31acquisition_additioncompletedUnited StatesHealth care bar coding technology; sports medicineMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisitions of IntelliCode Intelligent Bar Coding Systems (MedPlus division) and Tru-Fit Marketing Corporation; combined annual revenues about $28 million. No headcount disclosed.
1997-12-31acquisition_additionannounced1998-01Medical Devices Division (MDD) of Ohmeda, The BOC Group health care businesssubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement signed January 1998; MDD annual revenues about $200 million; expected completion in fiscal Q3 1998 subject to government approvals. No headcount disclosed.
1997-09-30acquisition_additioncompleted1997-05Diagnostic Systemsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		PharMingen, a biomedical research reagents manufacturer, acquired in May 1997. Headcount added not disclosed. Combined PharMingen and Difco purchase price was $187.2 million net of cash acquired.
1997-09-30acquisition_additioncompleted1997-05Diagnostic Systemsbusiness_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Difco Laboratories, a microbiology media and supplies manufacturer, acquired in May 1997. Headcount added not disclosed.
1997-09-30plant_closurein_progress1997-05Diagnostic Systems (Difco)USD 17,813 (thousands)business_combinations_footnote
f5-10k / GLM-5.3-flash-HTML		Liability assumed in the Difco acquisition covers severance and other exit costs for closing certain Difco facilities; affected employee count not disclosed.
1997-09-30restructuringin_progressUnited States and EuropeUSD 5,963 (thousands)other
f5-10k / GLM-5.3-flash-HTML		Curtailment loss recorded in fiscal 1997 for severance connected with productivity programs in the United States and Europe; no headcount disclosed.
1997-09-30divestiture_reductioncompleted1996-10Medical Supplies and DevicesItem_1_Business
f5-10k / GLM-5.3-flash-HTML		Syringe pump business sold in October 1996 (first month of fiscal 1997). MD&A reports fiscal 1997 divestiture proceeds of $24 million including an infusion systems business; headcount not disclosed.
1997-09-30divestiture_reductioncompletedDiagnostic SystemsMD&A
f5-10k / GLM-5.3-flash-HTML		Small product line related to the microbiology business divested during fiscal 1997 as part of divestitures that generated $24 million in aggregate proceeds; headcount not disclosed.
1997-09-30acquisition_additioncompleted1997-05-011997-05-31United StatesDiagnostic SystemsUSD 15 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		PharMingen and Difco Laboratories acquired May 1997 for $187.2M net of cash; $14.75M in-process R&D charge. No headcount added disclosed.
1997-09-30divestiture_reductioncompleted1996-10-31Medical Supplies and DevicesItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Syringe pump business sold in October 1996; no headcount reduction disclosed.
1997-09-30restructuringcompletedUnited States and EuropeUSD 6 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Curtailment loss for severance tied to productivity programs in US and Europe; employee count not disclosed.
1997-09-30restructuringcompletedUnited States and EuropeUSD 5,963 (thousands)Note 4 - Benefit Plans
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		In 1997, the Company recorded a $5,963 thousand curtailment loss for severance in connection with productivity programs in the United States and Europe. Employee count not disclosed.
1997-09-30restructuringcompletedUnited States and EuropeUSD 5,963 (thousands)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Recorded $5,963 thousand curtailment loss for severance in connection with productivity programs.
1997-09-30acquisition_additioncompleted1997-05WorldwideDiagnostic Systemsbusiness_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquired PharMingen and Difco Laboratories in May 1997. Headcount not explicitly disclosed.
1997-09-30divestiture_reductioncompletedWorldwideMD&A
f5-10k / Qwen3.6-27B-Q8_0		Divested infusion systems business and small microbiology product line. Headcount not explicitly disclosed.
1997-06-30acquisition_additioncompletedBiomedical research (PharMingen); microbiology media and supplies (Difco Laboratories)USD 187 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Aggregate purchase price of $187 million, net of cash acquired, for PharMingen and Difco Laboratories in the quarter; no employee headcount added disclosed.
1996-12-31divestiture_reductioncompletedEuropeMedical Supplies and Devices (infusion pump business)MD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale of European infusion pump business completed in the quarter; $21 million proceeds collected. Headcount impact not disclosed. MD&A also cites absence of about $27 million of divested-business revenues in Medical Supplies and Devices.
1996-09-30divestiture_reductioncompleted1996-011996-01Not disclosedContract packaging services businessItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Contract packaging services business sold in January 1996; no headcount associated with the sale disclosed
1996-09-30divestiture_reductioncompleted1996-081996-08Not disclosedPre-surgery patient prep businessItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Pre-surgery patient prep business sold in August 1996; no headcount associated with the sale disclosed
1996-09-30acquisition_additioncompleted1996-071996-07United StatesMedical Supplies and Devices — sharps disposal containersbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Med-Safe Systems, Inc. acquired July 1996; acquisition consideration of $16,501 thousand shown in cash flow statement; acquired headcount not disclosed
1996-03-31divestiture_reductioncompleted1996-02Contract packaging businessother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Sale consummated February 1996 with a pre-tax gain of about $2 million; no employee impact disclosed.
1996-03-31divestiture_reductioncompletedSmall surgical product lineMD&A
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Divestiture occurred during the quarter; proceeds of about $30 million collected in the first six months across this and the contract packaging divestiture; no employee impact disclosed.
1995-09-30divestiture_reductioncompleted1995-06-30Medical Supplies and DevicesUSD 6,301 (thousands)Item_1_Business
f5-10k / GLM-5.3-flash-HTML		Medical glove business sold June 30, 1995 (date reflects completed sale; no separate announcement date disclosed). Headcount of the divested business not disclosed. Charge is a loss on sale, not a severance charge.
1995-09-30divestiture_reductioncompleted1995-05Diagnostic SystemsItem_1_Business
f5-10k / GLM-5.3-flash-HTML		Radioimmunoassay (RIA) business sold in May 1995 (month-only date disclosed; reflects completed sale). Headcount and standalone financial impact of the divested business not disclosed.
1995-09-30divestiture_reductioncompleted1995-05-011995-05-31Not specifiedDiagnostic SystemsItem_1_Business
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Radioimmunoassay business sold in May 1995; no headcount impact disclosed.
1995-09-30divestiture_reductioncompleted1995-06-011995-06-30Not specifiedMedical Supplies and DevicesUSD 6 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Medical glove business sold June 30, 1995 with a $6.3M loss on sale; no headcount impact disclosed. Revenue from this business was $85M in 1995.
1995-09-30divestiture_reductioncompletedWorldwideMedical Supplies and DevicesItem 1. Business - Dispositions of Businesses
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Company sold medical glove business in June 1995. Employee count not disclosed.
1995-09-30divestiture_reductioncompletedWorldwideDiagnostic SystemsItem 1. Business - Dispositions of Businesses
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		Company sold radioimmunoassay business in May 1995. Employee count not disclosed.
1995-09-30voluntary_separationcompletedUnited StatesCorporateUSD 5,000 (thousands)MD&A
f5-10k / Qwen3.6-27B-NVFP4-MTP-HTML		One-time expense of $5 million recorded in 1994 for early retirement program offered to eligible employees. Employee count not disclosed.
1995-09-30voluntary_separationcompleted1994United StatesUSD 5 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		One-time expense of $5 million in connection with an early retirement program offered to certain eligible employees in 1994.